<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02688387</url>
  </required_header>
  <id_info>
    <org_study_id>201964</org_study_id>
    <nct_id>NCT02688387</nct_id>
  </id_info>
  <brief_title>A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects</brief_title>
  <official_title>A Phase 1 Study to Demonstrate the Relative Bioavailability of Fixed Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance Harrogate</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hammersmith Medicines Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to understand the relative bioavailability (proportion of the
      administered dose that is absorbed into the bloodstream) of several fixed dose combinations
      (FDCs) tablets of ambrisentan and tadalafil for further development and to provide
      pharmacokinetic (PK - what the body does to the drug) data to enable a pivotal bioequivalence
      (BE - the relationship between two preparations of the same drug in the same dosage form that
      have a similar bioavailability) study. Depending on formulation work, the study will allow up
      to 8 new FDCs to be compared with the reference of ambrisentan and tadalafil monotherapies.
      The study will also evaluate up to 2 of the new formulations, that may be taken in to a BE
      study, to be tested for any effect on pharmacokinetics of the FDC in both fed and fasted
      state. This is a single centre, Phase 1, single dose, randomised, open label crossover study
      with 3 study parts; each study part will have up to a 5 way crossover in healthy subjects.
      Part 1 of the study will evaluate four formulations of the FDC (ambrisentan 10 milligram [mg]
      + tadalafil 40 mg) and the reference of the 2 monotherapy components taken concurrently
      (ambrisentan 10 mg and tadalafil 40 mg) in the fasted stated. If successful formulations are
      identified in this part of the study, then they will be re-formulated and tested in part 2.
      If no successful formulations are identified in part 1 of the study, then part 2 will be
      utilized to look at up to 4 new FDC formulations. However, if only two formulations, or less,
      are evaluated in part 2 then the FDC formulations may be tested both fed and fasted to assess
      food effect and part 3 will not be required. If successful formulations are identified in
      this study part, then up to 2 of these may be tested, for food effect, in Part 3 if not
      already assessed in this part. Therefore, part 3 is optional and utility is dependent on the
      results of the previous study parts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 18, 2016</start_date>
  <completion_date type="Actual">August 4, 2017</completion_date>
  <primary_completion_date type="Actual">August 4, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Concentration (Cmax) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg &amp; Tadalafil 40 mg) - Part 1</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected at the indicated time points for analysis of ambrisentan and tadafil. The analysis was done under fasting condition post single dose. There is no formal hypotheses tested for Part 1 of the study. The analysis was performed on Pharmacokinetic (PK) parameter population, which included all participants who provided PK parameter data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinite (Inf) Time, AUC (0-inf) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg &amp; Tadalafil 40 mg) - Part 1</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples were collected at the indicated time-points. The analysis was done under fasting condition post single dose. There is no formal hypothesis tested for Part 1 of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC From Time of Dose to Last Measurable Concentration (AUC [0-t]), in FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fasting- Part 1</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples at Part 1, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours. The analysis was done under fasting condition post single dose. The PK Parameter Population was used for analysis. There is no formal hypotheses tested for Part 1 of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg &amp; Tadalafil 40 mg) - Part 2</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected at the indicated time-points, of Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. There is no formal hypotheses tested for Part 2 of the study. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0 - Inf) for FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fasting- Part 2</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 2, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis, was done under fasting condition post single dose. PK parameter Populatio was used for analysis. There is no formal hypotheses tested for Part 2 of the study. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t) for FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fasting- Part 2</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 2, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours. The analysis was done under fasting condition post single dose. PK parameter Population was used for analysis. There is no formal hypotheses tested for Part 2 of the study. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fed and Fasted Conditions-Part 3A</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3A, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fed and fasting condition post single dose. PK parameter population was used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-inf) for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fed and Fasted Conditions-3A</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3A, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48 and 72 hours post-dose. The analysis, was done under fed and fasting conditions post single dose. PK parameter population was used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t) for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fed and Fasted Conditions-Part 3A</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3A, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fed and fasting condition post single dose. PK parameter population was used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 40 mg) Under Fasted Conditions-3B</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-inf) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 40 mg) Under Fasted Conditions-3B</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36,48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK Parameter Population was used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 40 mg) Under Fasted Conditions-3B</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK parameter population was used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 20 mg) Under Fasted Conditions-3B</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK parameter population was used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-inf) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 20 mg) Under Fasted Conditions-3B</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis, was done under fasting conditions post single dose. PK parameter population was used for analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (0-t) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 20 mg) Under Fasted Conditions- Part 3B</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK parameter population was used for analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 1</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Serial blood samples were collected at the indicated time-points. In Part 3A, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 2</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Serial blood samples were collected at the indicated time-points. In Part 3A, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 3A</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Serial blood samples were collected at the indicated time-points. In Part 3A, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 3B</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>Serial blood samples were collected at the indicated time-points. In Part 3B, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Half Life (t1/2) for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part1</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 2</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 3A</measure>
    <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
    <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value. The serial blood samples were assessed at specified timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 3B</measure>
    <time_frame>Pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48, and 72 hours postdose</time_frame>
    <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value. The serial blood samples were assessed at specified timepoints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), Part 1</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP and DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1. Safety population included all the participants enrolled into the study who received atleast one dose of investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs-Heart Rate, Part 1</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Heart rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital- Temperature, Part 1</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs-Respiratory Rate, Part 1</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital- SBP and DBP, Part 2</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP and DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs-Heart Rate, Part 2</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Heart rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1. Safety population included all the participants enrolled into the study who received atleast one dose of investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital- Temperature, Part 2</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1. Safety population included all the participants enrolled into the study who received atleast one dose of investigational product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs-Respiratory Rate, Part 2</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital- SBP and DBP, Part 3A</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP, DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs-Heart Rate, Part 3A</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Heart rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital- Temperature, Part 3A</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs-Respiratory Rate, Part 3A</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital- SBP and DBP, Part 3B</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP and DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs-Heart Rate, Part 3B</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for HR. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital- Temperature, Part 3B</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Vital Signs-Respiratory Rate, Part 3-B</measure>
    <time_frame>Baseline and Up to Day 3</time_frame>
    <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Electrocardiogram (ECG) Findings, -Part 1</measure>
    <time_frame>Up to Day 3</time_frame>
    <description>12-lead ECG, was measured in semi-supine position after 5 minutes rest. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal ECG Findings, -Part 2</measure>
    <time_frame>Up to Day 3</time_frame>
    <description>12-lead ECG, were measured in semi-supine position after 5 minutes rest. It was conducted as triplicate at screen and baseline, whereas single measure at other times, unless out of range then triplicates were performed. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal ECG Findings, -Part 3A</measure>
    <time_frame>Up to Day 3</time_frame>
    <description>12-lead ECG, were measured in semi-supine position after 5 minutes rest. It was conducted as triplicate at screen and baseline, whereas single measure at other times, unless out of range then triplicates were performed. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal ECG Findings, -Part 3B</measure>
    <time_frame>Up to Day 3</time_frame>
    <description>12-lead ECG, were measured in semi-supine position after 5 minutes rest. It was conducted as triplicate at screen and baseline, whereas single measure at other times, unless out of range then triplicates were performed. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Values of Potential Clinical Importance (PCI)- Part1</measure>
    <time_frame>Up to Day 3</time_frame>
    <description>Blood samples were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Values of PCI - Part 2</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Values of PCI - Part 3A</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. It was conducted at Day 2 (48 hours). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hematology Values of PCI - Part 3B</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. It was conducted at Day 2 (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Chemistry Values of PCI- Part1</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Chemistry Values of PCI- Part 2</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. It was collected at Day 2 (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Chemistry Values of PCI- Part 3A</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. It was collected at (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical Chemistry Values of PCI- Part 3B</measure>
    <time_frame>Day 2</time_frame>
    <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. It was collected at Day 2 (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Urinalysis Results by Dipstick Method-Part 1</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urinalysis Results by Dipstick Analysis-Part 2</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urinalysis Results by Dipstick Analysis-Part 3A</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Urinalysis Results by Dipstick Analysis-Part 3B</measure>
    <time_frame>Up to Day 2</time_frame>
    <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs)-Part 1</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With SAEs and AEs-Part 2</measure>
    <time_frame>Up to 35 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With SAEs and AEs-Part 3A</measure>
    <time_frame>Up to 44 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With SAEs and AEs-Part 3B</measure>
    <time_frame>Up to 44 days</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC1, FDC2, FDC3 and FDC4, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDC and reference formulations contains 10 mg ambrisentan and 40 mg tadalafil. Each dosing period will be separated by 7 days wash out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects will receive single oral dose of 4 FDCs i.e., FDC5, FDC6, FDC7 and FDC8, and reference formulations of the 2 monotherapy components taken concurrently in the fasted state. The FDCs and reference formulations contains 10 mg ambrisentan and 40mg Tadalafil. OR Subjects will receive single dose of two FDCs from Part 1 in fed and fasted state. Each dosing period will be separated by 7 days wash out period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enrolled subjects will receive single oral dose of 2 FDCs from Part 2 in fed and fasted state. The FDCs contains 10 mg ambrisentan and 40 mg Tadalafil. Each dosing period will be separated by 7 days wash out period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose</intervention_name>
    <description>The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_label>Part 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)</intervention_name>
    <description>Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between 18 and 60 years of age inclusive, at the time of signing the informed consent.

          -  Healthy as determined by a responsible and experienced physician, based on a medical
             evaluation including medical history, physical examination, laboratory tests, vital
             signs and cardiac monitoring (ECG and 24 hour Holter). A subject with a clinical
             abnormality or laboratory parameter(s) which is/are not specifically listed in the
             inclusion or exclusion criteria, outside the reference range for the population being
             studied may be included only if the Investigator, in consultation with Medical Monitor
             if required, judges and documents that the finding is unlikely to introduce additional
             risk factors and will not interfere with the study procedures.

          -  Body weight &gt;= 50 Kilogram (kg) (110 pounds [lbs]) for men and &gt;= 45 kg (99lbs) for
             women and body mass index (BMI) within the range 18 - 30 kg per square metre (m^2)
             (inclusive)

          -  Male or Female. Female with non-reproductive potential defined as, Pre-menopausal
             females with one of the following: Documented tubal ligation or Documented
             hysteroscopic tubal occlusion procedure with follow-up confirmation of bilateral tubal
             occlusion or Hysterectomy or Documented Bilateral Oophorectomy, Documented
             Postmenopausal defined as 12 months of spontaneous amenorrhea

          -  Capable of giving signed informed consent.

        Exclusion Criteria:

          -  A blood pressure &lt;100/55 millimetre of Mercury (mm Hg).

          -  Haemoglobin (Hb) below normal range: Hb &lt;133 (gram per litre) g/L for males and Hb
             &lt;114 g/L for females

          -  Alanine amino transferase (ALT) and bilirubin &gt;1.5 x upper limit of normal (ULN)
             (isolated bilirubin &gt;1.5xULN is acceptable if bilirubin is fractionated and direct
             bilirubin is &lt;35 percentage [%]).

          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities
             (with the exception of Gilbert's syndrome or asymptomatic gallstones)

          -  Corrected QT (QTc) &gt;450 milliseconds (msec). The QTc is the QT interval corrected for
             heart rate according to Bazett's formula (QTcB), Fridericia's formula (QTcF), and/or
             another method, machine-read or manually over-read.

          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary
             supplements (including St John's Wort) within 7 days (or 14 days if the drug is a
             potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first
             dose of study medication, unless in the opinion of the Investigator and Medical
             Monitor the medication will not interfere with the study procedures or compromise
             subject safety.

          -  History of regular alcohol consumption within 6 months of the study defined as: An
             average weekly intake of &gt;21 units for males or &gt;14 units for females. One unit is
             equivalent to 8 gram (g) of alcohol: a half-pint (~240 millilitre [mL]) of beer, 1
             glass (125 mL) of wine or 1 (25 mL) measure of spirits.

          -  Smoking more than 5 cigarettes per week and subjects must be able to abstain from
             smoking for a 24 hour period prior to dose and any time whilst in the clinical unit.

          -  History of sensitivity to any of the study medications, or components thereof or a
             history of drug or other allergy that, in the opinion of the Investigator or Medical
             Monitor, contraindicates their participation.

          -  Presence of hepatitis B surface antigen (HBsAg), positive hepatitis C antibody test
             result at Screening or within 3 months prior to first dose of study treatment.

          -  A positive test for human immuno-deficiency virus (HIV) antibody

          -  A positive pre-study drug/alcohol screen.

          -  Where participation in the study would result in donation of blood or blood products
             in excess of 500 mL within previous 3 months

          -  The subject has participated in a clinical trial and has received an investigational
             product within the following time period prior to the first dosing day in the current
             study: 3 months, 5 half-lives or twice the duration of the biological effect of the
             investigational product (whichever is longer).

          -  Exposure to more than four new chemical entities within 12 months prior to the first
             dosing day.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2016</study_first_posted>
  <results_first_submitted>July 31, 2018</results_first_submitted>
  <results_first_submitted_qc>July 31, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 22, 2019</results_first_posted>
  <last_update_submitted>July 31, 2018</last_update_submitted>
  <last_update_submitted_qc>July 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ambrisentan</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Tadalafil</keyword>
  <keyword>Fixed Dose combination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ambrisentan</mesh_term>
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02688387/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02688387/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a single dose, randomized, open-label, crossover study in healthy participants. A total of 112 healthy participants were randomized and received the study treatment. The study was conducted at a single center in the United Kingdom.</recruitment_details>
      <pre_assignment_details>A total of 174 participants were screened, of which 59 were screen failures and 3 participants were reserve participants. Thus 112 participants were randomized. The study, was conducted in three parts: Part 1 (5 way crossover) and Parts 2 and 3 (A and B), followed 4 way crossover design.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1, F2/ F3/ F1/ F4/ R</title>
          <description>The eligible participants in the Sequence (F2/ F3/ F1/ F4/ R) received a single oral dose of fixed dose combination (FDC) for GSK3380154 (ambrisentan 10 milligram [mg] + tadalafil 40 mg). Participants received single oral dose F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg Sodium laurilsulfate [SLS]) during Period 1, followed by single oral dose F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS) during Period 2, followed by single oral dose F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS) during Period 3, followed by a single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS) during Period 4, which was followed by a single oral dose of R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil, taken concurrently, during Period 5. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P2">
          <title>Part 1, R/ F1/ F4/ F2/ F3</title>
          <description>The eligible participants in the Sequence (R/ F1/ F4/ F2/ F3), received a single oral dose of FDC for GSK3380154 (ambrisentan 10 mg + tadalafil 40 mg). Participants received single oral dose of R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil, taken concurrently, during Period 1, followed by single oral dose of F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS) during Period 2, followed by a single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS) during Period 3, followed by single oral dose F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS during Period 4, followed by single oral dose F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS) during Period 5.Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P3">
          <title>Part 1, F4/ F3/ R/ F2/ F1</title>
          <description>The eligible participants in the Sequence (F4/ F3/ R/ F2/ F1), received a single oral dose of FDC for GSK3380154 (ambrisentan 10 mg + tadalafil 40 mg). Participants received single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS) during Period 1, followed by single oral dose F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS) during Period 2, followed by single oral dose of R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil, taken concurrently, during Period 3, followed by single oral dose F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, during Period 4, followed by single oral dose of F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS), during Period 5. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P4">
          <title>Part 1, F2/ F1/ F3/ R/ F4</title>
          <description>The eligible participants in the Sequence (F2/ F1/ F3/ R/ F4), received a single oral dose of FDC for GSK3380154 (ambrisentan 10 mg + tadalafil 40 mg). Participants received single oral dose of F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, during Period 1, followed by single oral dose of F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS), during Period 2, followed by single oral dose F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS) during Period 3, followed by single oral dose of R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil, taken concurrently, during Period 4, followed by single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS) during Period 5. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P5">
          <title>Part 1, F3/ F2/ F4/ F1/ R</title>
          <description>The eligible participants in the Sequence (F3/ F2/ F4/ F1/ R), received a single oral dose of FDC for GSK3380154 (ambrisentan 10 mg + tadalafil 40 mg). Participants received single oral dose of F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS), during Period 1, followed by a single oral dose of F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, during Period 2, followed by single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS) during Period 3, followed by single oral dose of F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS), during Period 4, followed by single oral dose of R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil, taken concurrently, during Period 5. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P6">
          <title>Part 1, F1/ F2/ R/ F3/ F4</title>
          <description>The eligible participants in the Sequence (F1/ F2/ R/ F3/ F4), received a single oral dose of FDC for GSK3380154 (ambrisentan 10 mg + tadalafil 40 mg). Participants received single oral dose of F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS) during Period 1, followed by a single oral dose of F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, during Period 2, followed by single oral dose of R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil, taken concurrently, during Period 3, followed by a single oral dose of F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS), during Period 4, followed by single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS)during Period 5. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P7">
          <title>Part 1, F3/ F4/ F2/ R/ F1</title>
          <description>The eligible participants in the Sequence (F3/ F4/ F2/ R/ F1), , received a single oral dose of FDC for GSK3380154 (ambrisentan 10 mg + tadalafil 40 mg). Participants received single oral dose of F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS), during Period 1, followed by single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS) during Period 2, followed by a single oral dose of F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, during Period 3, followed by a single oral dose of F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, during Period 4, followed by received single oral dose of F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS) during Period 5. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P8">
          <title>Part 1, F4/ R/ F3/ F1/ F2</title>
          <description>The eligible participants in the Sequence (F4/ R/ F3/ F1/ F2), received a single oral dose of FDC for GSK3380154 (ambrisentan 10 mg + tadalafil 40 mg). Participants received single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS)during Period 1, followed by a single oral dose of R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil, taken concurrently during Period 2,followed by a single oral dose of F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS), during Period 3, followed single oral dose of F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS), during Period 4, followed by a single oral dose of F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, during Period 5. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P9">
          <title>Part 1, R/ F4/ F1/ F3/ F2</title>
          <description>The eligible participants in the Sequence (R/ F4/ F1/ F3/ F2), received a single oral dose of FDC for GSK3380154 (ambrisentan 10 mg + tadalafil 40 mg). Participants received single oral dose of R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil, taken concurrently during Period 1, followed by a single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS) during Period 2, followed single oral dose of F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS), during Period 3, followed by a single oral dose of F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS), during Period 4, followed by a s ingle oral dose of F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, during Period 5. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P10">
          <title>Part 1, F1/ R/ F2/ F4/ F3</title>
          <description>The eligible participants in the Sequence (F1/ R/ F2/ F4/ F3), received a single oral dose of FDC for GSK3380154 (ambrisentan 10 mg + tadalafil 40 mg). Participants received single oral dose of F1(FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS),during Period 1, followed by single oral dose of R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil, taken concurrently during Period 2, followed by a s ingle oral dose of F2 (FDC 2-GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, during Period 3, followed by a single oral dose of F4 (FDC4- GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS) during Period 4, followed by a single oral dose of F3 (FDC 3- GSK3380154, TAB-A, Tablet Weight 560mg/2mg SLS), during Period 5. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P11">
          <title>Part 2, R/ FG1/ FG3/ FG2</title>
          <description>The eligible participants in the Sequence (R/ FG1/ FG3/ FG2) were administered the 2 monotherapies ambrisentan and tadalafil concurrently, during Period 1, this was followed by single oral dose of FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg), with formulation selected from Part 1, during Period 2, this was followed by the single oral dose of FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1 during Period 3, this was followed by single oral dose of the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1, administered during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P12">
          <title>Part 2, FG1/FG2/R/ FG3</title>
          <description>The eligible participants in the Sequence (FG1/FG2/R/ FG3) were administered single oral dose of FG1 given as FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg), with formulation selected from Part 1, during Period 1, this was followed by the single oral dose of FG2 given as FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1 during Period 2, this was followed by the 2 monotherapies R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil concurrently, from the formulation selected from Part 1, given during Period 3, this was followed by single oral dose of FG3 given as FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1, administered during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P13">
          <title>Part 2, FG2/ FG3/ FG1/ R</title>
          <description>The eligible participants in the Sequence (FG2/ FG3/ FG1/ R), were administered single oral dose of FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1 during Period 1, this was followed by single oral dose of the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1, administered during Period 2, this was followed by single oral dose of FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg), with formulation selected from Part 1, during Period 3, this was followed by the 2 monotherapies R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil concurrently, from the formulation selected from Part 1, given during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P14">
          <title>Part 2, FG3/ R/ FG2/ FG1</title>
          <description>The eligible participants in the Sequence (FG3/ R/ FG2/ FG1),were administered with single oral dose of the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1, administered during Period 1, this was followed by the 2 monotherapies R, a Reference- single monotherapies of 10 mg ambrisentan and 20 mg of tadalafil concurrently, from the formulation selected from Part 1, given during Period 2, this was followed by single oral dose of FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1 during Period 3, this was followed by single oral dose of FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg), with formulation selected from Part 1, during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 7-Days.</description>
        </group>
        <group group_id="P15">
          <title>Part 3A, X2/ R2/ R1/ X1</title>
          <description>Eligible participants received single oral dose of X2 as FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (granular formulation selected from Part 2), under fasted state during Period 1, followed by single oral dose of R2 where participants had received 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state during Period 2, this was followed by a single oral dose of R1 where participants had received 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state, comprising of high fat diet during Period 3, followed by a single oral dose of X1 where participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state, which comprised of high fat diet, during Period 4. Overall treatment period was of 4-weeks. Each dose taken either under fed or fasted condition and separated by washout period of 10-Days.</description>
        </group>
        <group group_id="P16">
          <title>Part 3A, ,X1/ R1/ R2/ X2</title>
          <description>Eligible participants received single oral dose of X1 where participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state, which comprised of a high fat diet, during Period 1, followed by single oral dose of R1 where participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state, comprising of high fat diet during Period 2, followed by single oral dose of R2 where participants had received 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state during Period 3, followed by single oral dose of X2 as FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state during Period 4. Overall treatment period was of 4-weeks. Each dose taken either under fed or fasted condition and separated by washout period of 10-Days.</description>
        </group>
        <group group_id="P17">
          <title>Part 3A, R1/ X2/ X1/ R2</title>
          <description>Eligible participants were administered single oral dose of R1 where participants had received 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state, comprising of high fat diet during Period 1, followed by single oral dose of X2 as FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state during Period 2, followed by single oral dose of X1 where participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state, comprising high fat diet, during Period 3, followed by single oral dose of R2 where participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 10-Days.</description>
        </group>
        <group group_id="P18">
          <title>Part 3A, ,R2/ X1/ X2/ R1</title>
          <description>Eligible participants were administered single oral dose of R2 where participants had received 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state during Period 1, followed by single oral dose of X1 where participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state, which comprised of high fat diet, during Period 2, followed by single oral dose of X2 as FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (granular formulation selected from Part 2), under fasted state during Period 3, followed by single oral dose of R1 where participants had received 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state, comprising high fat diet during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fed or fasted condition and separated by washout period of 10-Days.</description>
        </group>
        <group group_id="P19">
          <title>Part 3B, Y1/ R3/ R4/ Y2</title>
          <description>The eligible participants in the Sequence (Y1/ R3/ R4/ Y2), where participants for Y1 dose were administered a single oral dose of FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose during Period 1, this was followed by a single oral dose of R3 the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg during Period 2, this was followed by a single oral dose of R4, where the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state, during Period 3, this was followed by Y2 dose where the participants received a single oral dose of received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state, during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 10-Days.</description>
        </group>
        <group group_id="P20">
          <title>Part 3B, R3/ Y2/ Y1/ R4</title>
          <description>The eligible participants in the Sequence (R3/ Y2/ Y1/ R4), where the participants for R3 dose were administered a single oral dose of the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose, during Period 1, this was followed by the Y2 dose, where the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose during Period 2, this was followed by the Y1 dose where the participants were administered a single oral dose of FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose during Period 3, this was followed by a single oral dose of R4, where the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state, during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 10-Days.</description>
        </group>
        <group group_id="P21">
          <title>Part 3B, Y2/ R4/ R3/ Y1</title>
          <description>The eligible participants in the Sequence (Y2/ R4/ R3/ Y1), received single oral dose of Y2 where the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose during Period 1, this was followed by a single oral dose of R4, where the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state, during Period 2, this was followed by a single oral dose of R3 dose where participants were administered a single oral dose of the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state, during Period 3, this was followed by the Y1 dose where the participants were administered a single oral dose of FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 10-Days.</description>
        </group>
        <group group_id="P22">
          <title>Part 3B, R4/ Y1/ Y2/ R3</title>
          <description>The eligible participants in the Sequence (R4/ Y1/ Y2/ R3), received single oral dose of R4, where the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state, during Period 1, this was followed by the Y1 dose where the participants were administered a single oral dose of FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose during Period 2, this was followed by single oral dose of Y2 where the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose during Period 3, this was followed by a single oral dose of R3 dose where participants were administered a single oral dose of the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state, during Period 4. Overall treatment period was of 4-weeks. Each dose was taken under fasted condition and separated by a washout period of 10-Days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part 1, Period 1 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1, Washout Period 1 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol defined stop criteria reached</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1, Period 2 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol defined stop criteria reached</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1, Washout Period 2 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Period 3 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Washout Period 3 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 1, Period 4 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Washout Period 4 (7 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 1, Period 5 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Period 1 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 2, Washout Period 1 (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Period 2 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Washout Period 2 (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Period 3 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Washout Period 3 (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 2, Period 4 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="5"/>
                <participants group_id="P12" count="5"/>
                <participants group_id="P13" count="5"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3A, Period 1 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="9"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 3A, Washout Period 1 (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3A, Period 2 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3A, Washout Period 2 (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3A, Period 3 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3A, Washout Period 3 (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3A, Period 4 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
                <participants group_id="P18" count="8"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3B, Period 1 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="8"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="8"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3B, Washout Period 1 (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="8"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="8"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3B, Period 2 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="8"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="8"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3B, Washout Period 2 (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="8"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="8"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Part 3B, Period 3 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="8"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="7"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="1"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="1"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 3B, Washout Period 3 (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="8"/>
                <participants group_id="P20" count="8"/>
                <participants group_id="P21" count="7"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="7"/>
                <participants group_id="P20" count="7"/>
                <participants group_id="P21" count="6"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="1"/>
                <participants group_id="P21" count="1"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="1"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="1"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="1"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part 3B, Period 4 (up to 6 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="7"/>
                <participants group_id="P20" count="7"/>
                <participants group_id="P21" count="6"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="7"/>
                <participants group_id="P20" count="7"/>
                <participants group_id="P21" count="6"/>
                <participants group_id="P22" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
                <participants group_id="P18" count="0"/>
                <participants group_id="P19" count="0"/>
                <participants group_id="P20" count="0"/>
                <participants group_id="P21" count="0"/>
                <participants group_id="P22" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part 1</title>
          <description>In Part 1, there were 5 dosing sessions of four formulations of the FDCs (ambrisentan 10 mg + tadalafil 40 mg) (F1, F2, F3, F4) and 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg (R) which were administered concurrently . The participants received a single oral dose of formulation or the reference during each session. All the doses were taken in fasted condition. The treatment period for Part 1 was of 4-weeks, post which there was a follow-up period of 14 days (which included 7-days washout)</description>
        </group>
        <group group_id="B2">
          <title>Part 2</title>
          <description>This comprised of 4 dose sessions, of 3 different granulation sizes for a single FDC (ambrisentan 10 mg +tadalafil 40 mg) compared to the reference of the 2 monotherapy components taken concurrently (ambrisentan 10 mg &amp; tadalafil 40 mg), to evaluate the bioavailability. This part of the study provided data for 3 granulation size forms of a single FDC formulation selected from Part 1. The participants received a single oral dose during each session. All the doses were taken in fasted condition. The treatment period for Part 2 was of 4-weeks, post which a follow-up period of 14 days (which included 7-days washout). Part 2 had FG1, FG2, FG3 which are Ambrisentan and Tadalafil FDCs (10mg/40mg). R is ambrisentan and tadalafil monotherapies taken concurrently (10mg/40mg).</description>
        </group>
        <group group_id="B3">
          <title>Part 3A</title>
          <description>This comprised of 4 dose sessions of the FDC against the reference ambrisentan 10 mg + tadalafil 40mg monotherapies in the fed and fasted state, taken to evaluate the bioequivalence. The participants received a single oral dose during each session, taken under fed and fasted conditions. The fed arms of this part of the study received a standard high fat breakfast. The treatment period of Part 3A was of 4-weeks, post which a follow-up period of 14 days (which included 10-days washout). In Part 3A, X1, X2 are ambrisentan and tadalafil FDCs (10mg/40mg),where X1 is under fed state and X2 is under fasted state. R1, R2 are Ambrisentan and Tadalafil monotherapies taken concurrently(10mg/40mg), where R1 is under fed state and R2 is under fasted state.</description>
        </group>
        <group group_id="B4">
          <title>Part 3B</title>
          <description>This study part comprised of 4 dose sessions which assessed the bioequivalence of the two FDC dose strengths, (ambrisentan 5 mg + tadalafil 40mg and ambrisentan 5 mg + tadalafil 20mg) against the reference ambrisentan 5 mg + tadalafil 40mg monotherapies and ambrisentan 5 mg + tadalafil 20mg monotherapies in the fasted state. The treatment period of Part 3B was of 4-weeks, post which there was a follow-up period of 14 days (which included 10-days washout). In the Part 3B, Y1, Y2 are ambrisentan and tadalafil FDCs, under fasted state, where Y1 is 5mg/40mg and Y2 is 5mg/20mg and R3, R4 are ambrisentan and tadalafil monotherapies taken concurrently, under fasted state, where R3 is 5mg/40mg and R4 is 5mg/20mg.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="33"/>
            <count group_id="B4" value="32"/>
            <count group_id="B5" value="112"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.7" spread="11.68"/>
                    <measurement group_id="B2" value="36.8" spread="12.07"/>
                    <measurement group_id="B3" value="37.3" spread="10.36"/>
                    <measurement group_id="B4" value="30.9" spread="12.05"/>
                    <measurement group_id="B5" value="35.5" spread="11.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race, Customized</title>
              <category_list>
                <category>
                  <title>Asian-Central/South Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian- South East Asian heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black Or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White - Arabic/North African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White/Caucasian/European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple-Asian and White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Concentration (Cmax) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg &amp; Tadalafil 40 mg) - Part 1</title>
        <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected at the indicated time points for analysis of ambrisentan and tadafil. The analysis was done under fasting condition post single dose. There is no formal hypotheses tested for Part 1 of the study. The analysis was performed on Pharmacokinetic (PK) parameter population, which included all participants who provided PK parameter data.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Concentration (Cmax) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg &amp; Tadalafil 40 mg) - Part 1</title>
          <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected at the indicated time points for analysis of ambrisentan and tadafil. The analysis was done under fasting condition post single dose. There is no formal hypotheses tested for Part 1 of the study. The analysis was performed on Pharmacokinetic (PK) parameter population, which included all participants who provided PK parameter data.</description>
          <population>PK parameter Population</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766.29" spread="18.2"/>
                    <measurement group_id="O2" value="685.33" spread="20.5"/>
                    <measurement group_id="O3" value="738.49" spread="22.1"/>
                    <measurement group_id="O4" value="722.57" spread="27.7"/>
                    <measurement group_id="O5" value="755.37" spread="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="581.41" spread="27.6"/>
                    <measurement group_id="O2" value="595.47" spread="22.3"/>
                    <measurement group_id="O3" value="588.11" spread="24.5"/>
                    <measurement group_id="O4" value="590.36" spread="21.4"/>
                    <measurement group_id="O5" value="567.62" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinite (Inf) Time, AUC (0-inf) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg &amp; Tadalafil 40 mg) - Part 1</title>
        <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples were collected at the indicated time-points. The analysis was done under fasting condition post single dose. There is no formal hypothesis tested for Part 1 of the study.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to Infinite (Inf) Time, AUC (0-inf) of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg &amp; Tadalafil 40 mg) - Part 1</title>
          <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples were collected at the indicated time-points. The analysis was done under fasting condition post single dose. There is no formal hypothesis tested for Part 1 of the study.</description>
          <population>PK parameter Population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, (AUC 0 - inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5566.06" spread="23.8"/>
                    <measurement group_id="O2" value="5556.44" spread="25.9"/>
                    <measurement group_id="O3" value="5788.91" spread="25.8"/>
                    <measurement group_id="O4" value="6007.57" spread="23.7"/>
                    <measurement group_id="O5" value="5746.73" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, (AUC 0 - inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13408.30" spread="41.3"/>
                    <measurement group_id="O2" value="14415.47" spread="41.8"/>
                    <measurement group_id="O3" value="14545.28" spread="38.4"/>
                    <measurement group_id="O4" value="14418.35" spread="37.8"/>
                    <measurement group_id="O5" value="13955.85" spread="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC From Time of Dose to Last Measurable Concentration (AUC [0-t]), in FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fasting- Part 1</title>
        <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples at Part 1, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours. The analysis was done under fasting condition post single dose. The PK Parameter Population was used for analysis. There is no formal hypotheses tested for Part 1 of the study.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC From Time of Dose to Last Measurable Concentration (AUC [0-t]), in FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fasting- Part 1</title>
          <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples at Part 1, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours. The analysis was done under fasting condition post single dose. The PK Parameter Population was used for analysis. There is no formal hypotheses tested for Part 1 of the study.</description>
          <population>PK Parameter Population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, (AUC 0- t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5418.03" spread="22.9"/>
                    <measurement group_id="O2" value="5434.88" spread="25.3"/>
                    <measurement group_id="O3" value="5655.75" spread="25.5"/>
                    <measurement group_id="O4" value="5858.18" spread="22.9"/>
                    <measurement group_id="O5" value="5605.58" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, (AUC 0- t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12469.86" spread="37.1"/>
                    <measurement group_id="O2" value="13307.95" spread="37.4"/>
                    <measurement group_id="O3" value="13376.86" spread="34.8"/>
                    <measurement group_id="O4" value="13238.89" spread="33.4"/>
                    <measurement group_id="O5" value="12805.01" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg &amp; Tadalafil 40 mg) - Part 2</title>
        <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected at the indicated time-points, of Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. There is no formal hypotheses tested for Part 2 of the study. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies, ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of Ambrisentan and Tadalafil in FDC (Ambrisentan 10 mg + Tadalafil 40 mg) and Montherapies (Ambrisentan 10 mg &amp; Tadalafil 40 mg) - Part 2</title>
          <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples were collected at the indicated time-points, of Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. There is no formal hypotheses tested for Part 2 of the study. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>PK parameter Population</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, (n=21,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="710.90" spread="28.2"/>
                    <measurement group_id="O2" value="720.79" spread="21.1"/>
                    <measurement group_id="O3" value="748.63" spread="22.9"/>
                    <measurement group_id="O4" value="726.15" spread="31.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, (n=20,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="537.80" spread="27.6"/>
                    <measurement group_id="O2" value="561.60" spread="28.4"/>
                    <measurement group_id="O3" value="550.78" spread="28.6"/>
                    <measurement group_id="O4" value="553.31" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0 - Inf) for FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fasting- Part 2</title>
        <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 2, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis, was done under fasting condition post single dose. PK parameter Populatio was used for analysis. There is no formal hypotheses tested for Part 2 of the study. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies, ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0 - Inf) for FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fasting- Part 2</title>
          <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 2, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis, was done under fasting condition post single dose. PK parameter Populatio was used for analysis. There is no formal hypotheses tested for Part 2 of the study. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>PK parameter Population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, AUC (0-inf) (n=21,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6029.19" spread="29.6"/>
                    <measurement group_id="O2" value="6179.41" spread="27.2"/>
                    <measurement group_id="O3" value="6189.22" spread="29.5"/>
                    <measurement group_id="O4" value="6201.40" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, AUC ( 0 - inf) (n=20,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14006.59" spread="46.7"/>
                    <measurement group_id="O2" value="14443.86" spread="44.8"/>
                    <measurement group_id="O3" value="14502.37" spread="40.5"/>
                    <measurement group_id="O4" value="14457.33" spread="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-t) for FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fasting- Part 2</title>
        <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 2, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours. The analysis was done under fasting condition post single dose. PK parameter Population was used for analysis. There is no formal hypotheses tested for Part 2 of the study. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies, ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t) for FDC, (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fasting- Part 2</title>
          <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 2, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours. The analysis was done under fasting condition post single dose. PK parameter Population was used for analysis. There is no formal hypotheses tested for Part 2 of the study. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>PK parameter Population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, (n=21,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5893.74" spread="29.4"/>
                    <measurement group_id="O2" value="6016.62" spread="27.1"/>
                    <measurement group_id="O3" value="6051.83" spread="29.6"/>
                    <measurement group_id="O4" value="6015.11" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, (n=20,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12832.91" spread="39.6"/>
                    <measurement group_id="O2" value="13149.19" spread="37.5"/>
                    <measurement group_id="O3" value="13305.50" spread="35.2"/>
                    <measurement group_id="O4" value="13275.08" spread="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fed and Fasted Conditions-Part 3A</title>
        <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3A, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fed and fasting condition post single dose. PK parameter population was used.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fed and Fasted Conditions-Part 3A</title>
          <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3A, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fed and fasting condition post single dose. PK parameter population was used.</description>
          <population>PK Parameter Population</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="550.02" spread="30.9"/>
                    <measurement group_id="O2" value="756.60" spread="24.1"/>
                    <measurement group_id="O3" value="515.61" spread="33.4"/>
                    <measurement group_id="O4" value="728.32" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525.10" spread="26.5"/>
                    <measurement group_id="O2" value="508.72" spread="24.9"/>
                    <measurement group_id="O3" value="533.67" spread="19.5"/>
                    <measurement group_id="O4" value="520.62" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0667</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9657</ci_lower_limit>
            <ci_upper_limit>1.1784</ci_upper_limit>
            <estimate_desc>X1 Vs R1, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0353</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9293</ci_lower_limit>
            <ci_upper_limit>1.1534</ci_upper_limit>
            <estimate_desc>X2 Vs R2, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.9839</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9288</ci_lower_limit>
            <ci_upper_limit>1.0423</ci_upper_limit>
            <estimate_desc>X1 Vs R1, tadalafil</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.9656</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9151</ci_lower_limit>
            <ci_upper_limit>1.0188</ci_upper_limit>
            <estimate_desc>X2 Vs R2, tadalafil</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-inf) for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fed and Fasted Conditions-3A</title>
        <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3A, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48 and 72 hours post-dose. The analysis, was done under fed and fasting conditions post single dose. PK parameter population was used.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-inf) for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fed and Fasted Conditions-3A</title>
          <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3A, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 48 and 72 hours post-dose. The analysis, was done under fed and fasting conditions post single dose. PK parameter population was used.</description>
          <population>PK Parameter Population.</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, AUC (0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6075.51" spread="26.1"/>
                    <measurement group_id="O2" value="6231.48" spread="25.1"/>
                    <measurement group_id="O3" value="5898.72" spread="27.7"/>
                    <measurement group_id="O4" value="6155.60" spread="24.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, AUC (0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16086.66" spread="41.5"/>
                    <measurement group_id="O2" value="14856.32" spread="40.0"/>
                    <measurement group_id="O3" value="16596.18" spread="37.8"/>
                    <measurement group_id="O4" value="14612.84" spread="41.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0300</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9965</ci_lower_limit>
            <ci_upper_limit>1.0646</ci_upper_limit>
            <estimate_desc>X1 Vs R1, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0141</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9820</ci_lower_limit>
            <ci_upper_limit>1.0473</ci_upper_limit>
            <estimate_desc>X2 Vs R2, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.9693</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9310</ci_lower_limit>
            <ci_upper_limit>1.0092</ci_upper_limit>
            <estimate_desc>X1 Vs R1, tadalafil</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0157</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9553</ci_lower_limit>
            <ci_upper_limit>1.0799</ci_upper_limit>
            <estimate_desc>X2 Vs R2, tadalafil</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-t) for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fed and Fasted Conditions-Part 3A</title>
        <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3A, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fed and fasting condition post single dose. PK parameter population was used.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t) for Ambrisentan and Tadalafil, Following Candidate FDC (Ambrisentan 10 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 10 mg &amp; Tadalafil 40 mg), Under Fed and Fasted Conditions-Part 3A</title>
          <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3A, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fed and fasting condition post single dose. PK parameter population was used.</description>
          <population>PK Parameter Population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, AUC (0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5926.87" spread="25.7"/>
                    <measurement group_id="O2" value="6090.74" spread="24.8"/>
                    <measurement group_id="O3" value="5766.71" spread="27.4"/>
                    <measurement group_id="O4" value="6012.51" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, AUC (0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14366.73" spread="33.7"/>
                    <measurement group_id="O2" value="13320.79" spread="32.4"/>
                    <measurement group_id="O3" value="14946.32" spread="31.1"/>
                    <measurement group_id="O4" value="13114.00" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0278</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9943</ci_lower_limit>
            <ci_upper_limit>1.0623</ci_upper_limit>
            <estimate_desc>X1 Vs R1, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0144</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9832</ci_lower_limit>
            <ci_upper_limit>1.0466</ci_upper_limit>
            <estimate_desc>X2 Vs R2, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.9612</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9265</ci_lower_limit>
            <ci_upper_limit>0.9972</ci_upper_limit>
            <estimate_desc>X1 Vs R1, tadalafil</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3A of the study is designed to test the bioequivalence of a FDC of ambrisentan 10 mg + tadalafil 40 mg (test) relative to reference monotherapies of ambrisentan 10 mg &amp; tadalafil 40 mg taken concurrently (reference) in healthy participants in both the fed and fasted states.</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0122</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9562</ci_lower_limit>
            <ci_upper_limit>1.0715</ci_upper_limit>
            <estimate_desc>X2 Vs R2, tadalafil</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 40 mg) Under Fasted Conditions-3B</title>
        <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 40 mg) Under Fasted Conditions-3B</title>
          <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose.</description>
          <population>PK Parameter Population</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375.87" spread="23.0"/>
                    <measurement group_id="O2" value="380.47" spread="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="488.36" spread="19.7"/>
                    <measurement group_id="O2" value="511.80" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0153</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9348</ci_lower_limit>
            <ci_upper_limit>1.1027</ci_upper_limit>
            <estimate_desc>Y1 Vs R3, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.9758</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9044</ci_lower_limit>
            <ci_upper_limit>1.0529</ci_upper_limit>
            <estimate_desc>Y1 Vs R3, tadalafil</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-inf) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 40 mg) Under Fasted Conditions-3B</title>
        <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36,48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK Parameter Population was used for analysis.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-inf) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 40 mg) Under Fasted Conditions-3B</title>
          <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36,48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK Parameter Population was used for analysis.</description>
          <population>PK Parameter Population</population>
          <units>Hour nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan AUC (0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3397.51" spread="19.7"/>
                    <measurement group_id="O2" value="3277.81" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, AUC (0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14724.34" spread="39.7"/>
                    <measurement group_id="O2" value="14938.29" spread="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0390</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0168</ci_lower_limit>
            <ci_upper_limit>1.0617</ci_upper_limit>
            <estimate_desc>Y1 Vs R3, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.9806</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9106</ci_lower_limit>
            <ci_upper_limit>1.0560</ci_upper_limit>
            <estimate_desc>Y1 Vs R3, tadalafil</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-t) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 40 mg) Under Fasted Conditions-3B</title>
        <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK parameter population was used for analysis.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 40 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 40 mg) Under Fasted Conditions-3B</title>
          <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK parameter population was used for analysis.</description>
          <population>PK parameter population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, AUC (0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3297.16" spread="19.8"/>
                    <measurement group_id="O2" value="3190.51" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, AUC (0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13119.89" spread="31.0"/>
                    <measurement group_id="O2" value="13325.63" spread="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0365</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0138</ci_lower_limit>
            <ci_upper_limit>1.0596</ci_upper_limit>
            <estimate_desc>Y1 Vs R3, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>0.9821</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9145</ci_lower_limit>
            <ci_upper_limit>1.0547</ci_upper_limit>
            <estimate_desc>Y1 Vs R3, tadalafil</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 20 mg) Under Fasted Conditions-3B</title>
        <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK parameter population was used.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 20 mg) Under Fasted Conditions-3B</title>
          <description>Cmax is defined as the maximum (or peak) plasma concentration that the drug achieves, after the drug has been administered. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK parameter population was used.</description>
          <population>PK parameter population</population>
          <units>Nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405.89" spread="25.1"/>
                    <measurement group_id="O2" value="358.89" spread="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340.63" spread="23.1"/>
                    <measurement group_id="O2" value="303.74" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.1176</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0166</ci_lower_limit>
            <ci_upper_limit>1.2287</ci_upper_limit>
            <estimate_desc>Y2 Vs R4, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.1196</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0429</ci_lower_limit>
            <ci_upper_limit>1.2019</ci_upper_limit>
            <estimate_desc>Y2 Vs R4, tadalafil</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-inf) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 20 mg) Under Fasted Conditions-3B</title>
        <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis, was done under fasting conditions post single dose. PK parameter population was used for analysis.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK Parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-inf) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 20 mg) Under Fasted Conditions-3B</title>
          <description>AUC (0- inf), is defined as area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity for ambrisentan and tadafil. Blood samples of 2.7 mL and 2 mL were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis, was done under fasting conditions post single dose. PK parameter population was used for analysis.</description>
          <population>PK Parameter Population.</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan AUC (0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3347.76" spread="20.9"/>
                    <measurement group_id="O2" value="3205.51" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, AUC (0-inf)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7962.14" spread="32.2"/>
                    <measurement group_id="O2" value="7748.47" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0353</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0009</ci_lower_limit>
            <ci_upper_limit>1.0710</ci_upper_limit>
            <estimate_desc>Y2 Vs R4, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0362</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9910</ci_lower_limit>
            <ci_upper_limit>1.0834</ci_upper_limit>
            <estimate_desc>Y2 Vs R4, tadalafil</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC (0-t) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 20 mg) Under Fasted Conditions- Part 3B</title>
        <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK parameter population was used for analysis.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC (0-t) for Ambrisentan and Tadalafil, FDCs (Ambrisentan 5 mg + Tadalafil 20 mg) Relative to Reference Monotherapies Tested (Ambrisentan 5 mg &amp; Tadalafil 20 mg) Under Fasted Conditions- Part 3B</title>
          <description>AUC (0-t), was defined as, the AUC measured from the time of dose to the last measurable concentration. Blood samples of 2.7 mL and 2 mL, were collected for ambrisentan and tadafil respectively. The plasma samples for Part 3B, were collected at the time-points pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48 and 72 hours post-dose. The analysis was done under fasting condition post single dose. PK parameter population was used for analysis.</description>
          <population>PK parameter population</population>
          <units>Hour*nanogram per milliliter</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan AUC (0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3254.70" spread="21.0"/>
                    <measurement group_id="O2" value="3116.10" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, AUC (0-t)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7264.28" spread="26.6"/>
                    <measurement group_id="O2" value="7076.48" spread="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0351</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.0002</ci_lower_limit>
            <ci_upper_limit>1.0713</ci_upper_limit>
            <estimate_desc>Y2 Vs R4, ambrisentan</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Part 3B of the study is set to establish bioequivalence between the Fixed Dose Combination of an additional two dose strengths (ambrisentan 5 mg + tadalafil 40 mg and ambrisentan 5 mg + tadalafil 20 mg).</non_inferiority_desc>
            <param_type>Ratio</param_type>
            <param_value>1.0324</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9929</ci_lower_limit>
            <ci_upper_limit>1.0734</ci_upper_limit>
            <estimate_desc>Y2 Vs R4, tadalafil</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 1</title>
        <description>Serial blood samples were collected at the indicated time-points. In Part 3A, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 1</title>
          <description>Serial blood samples were collected at the indicated time-points. In Part 3A, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax.</description>
          <population>PK parameter Population.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.000" lower_limit="0.50" upper_limit="8.23"/>
                    <measurement group_id="O2" value="1.500" lower_limit="0.53" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.500" lower_limit="0.52" upper_limit="4.00"/>
                    <measurement group_id="O4" value="1.500" lower_limit="0.57" upper_limit="4.05"/>
                    <measurement group_id="O5" value="1.500" lower_limit="0.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadafil, Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="0.50" upper_limit="8.23"/>
                    <measurement group_id="O2" value="2.000" lower_limit="0.50" upper_limit="8.03"/>
                    <measurement group_id="O3" value="2.000" lower_limit="0.50" upper_limit="8.00"/>
                    <measurement group_id="O4" value="2.000" lower_limit="0.50" upper_limit="8.00"/>
                    <measurement group_id="O5" value="1.500" lower_limit="0.50" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 2</title>
        <description>Serial blood samples were collected at the indicated time-points. In Part 3A, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies, ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 2</title>
          <description>Serial blood samples were collected at the indicated time-points. In Part 3A, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>PK parameter population.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, Tmax (n=21,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="0.50" upper_limit="4.03"/>
                    <measurement group_id="O2" value="1.500" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="1.500" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O4" value="1.508" lower_limit="1.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadafil, Tmax (n=20,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.017" lower_limit="0.50" upper_limit="8.02"/>
                    <measurement group_id="O2" value="1.750" lower_limit="0.50" upper_limit="8.08"/>
                    <measurement group_id="O3" value="2.000" lower_limit="0.50" upper_limit="8.00"/>
                    <measurement group_id="O4" value="2.000" lower_limit="0.50" upper_limit="12.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 3A</title>
        <description>Serial blood samples were collected at the indicated time-points. In Part 3A, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 3A</title>
          <description>Serial blood samples were collected at the indicated time-points. In Part 3A, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax.</description>
          <population>PK parameter Population.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="1.00" upper_limit="12.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="0.50" upper_limit="4.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="1.00" upper_limit="12.15"/>
                    <measurement group_id="O4" value="2.000" lower_limit="1.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadafil, Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.000" lower_limit="0.50" upper_limit="12.02"/>
                    <measurement group_id="O2" value="2.500" lower_limit="0.50" upper_limit="12.02"/>
                    <measurement group_id="O3" value="8.000" lower_limit="1.50" upper_limit="12.15"/>
                    <measurement group_id="O4" value="2.258" lower_limit="0.50" upper_limit="8.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 3B</title>
        <description>Serial blood samples were collected at the indicated time-points. In Part 3B, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time Taken to Reach Maximum Concentration (Tmax) for Ambrisentan and Tadalafil in FDC and Reference Treatment - Part 3B</title>
          <description>Serial blood samples were collected at the indicated time-points. In Part 3B, tmax was determined for ambrisentan and tadalafil when administered in FDC (10mg/40mg) under fed state and fasted state and as reference monotherapies (ambrisentan 10 mg and tadalafil 40 mg). PK parameter population was used to measure the tmax.</description>
          <population>PK parameter Population.</population>
          <units>Hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.767" lower_limit="1.00" upper_limit="4.03"/>
                    <measurement group_id="O2" value="1.500" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.000" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.758" lower_limit="1.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadafil, Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.500" lower_limit="0.50" upper_limit="8.00"/>
                    <measurement group_id="O2" value="1.500" lower_limit="0.50" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.500" lower_limit="0.50" upper_limit="8.00"/>
                    <measurement group_id="O4" value="2.008" lower_limit="0.50" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Half Life (t1/2) for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part1</title>
        <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg Sodium laurilsulfate (SLS), with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Half Life (t1/2) for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part1</title>
          <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value.</description>
          <population>PK parameter Population.</population>
          <units>Hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.74" spread="18.2"/>
                    <measurement group_id="O2" value="15.25" spread="19.2"/>
                    <measurement group_id="O3" value="15.76" spread="17.3"/>
                    <measurement group_id="O4" value="15.25" spread="20.0"/>
                    <measurement group_id="O5" value="16.08" spread="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.08" spread="30.4"/>
                    <measurement group_id="O2" value="17.76" spread="33.3"/>
                    <measurement group_id="O3" value="18.38" spread="33.3"/>
                    <measurement group_id="O4" value="18.48" spread="33.0"/>
                    <measurement group_id="O5" value="18.04" spread="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 2</title>
        <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 2</title>
          <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).</description>
          <population>PK parameter Population.</population>
          <units>Hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, t1/2 (n=21,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.19" spread="24.5"/>
                    <measurement group_id="O2" value="15.76" spread="33.3"/>
                    <measurement group_id="O3" value="15.39" spread="18.6"/>
                    <measurement group_id="O4" value="16.60" spread="34.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, t1/2, (n=20,20,20,20)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.58" spread="30.6"/>
                    <measurement group_id="O2" value="18.63" spread="33.2"/>
                    <measurement group_id="O3" value="18.22" spread="33.2"/>
                    <measurement group_id="O4" value="17.98" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 3A</title>
        <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value. The serial blood samples were assessed at specified timepoints.</description>
        <time_frame>Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 18, 24, 36, 48 and 72 hours post-dose</time_frame>
        <population>PK parameter population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 3A</title>
          <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value. The serial blood samples were assessed at specified timepoints.</description>
          <population>PK parameter population</population>
          <units>Hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.65" spread="16.7"/>
                    <measurement group_id="O2" value="15.42" spread="15.9"/>
                    <measurement group_id="O3" value="14.66" spread="13.7"/>
                    <measurement group_id="O4" value="15.63" spread="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.09" spread="34.4"/>
                    <measurement group_id="O2" value="19.85" spread="34.2"/>
                    <measurement group_id="O3" value="19.29" spread="33.4"/>
                    <measurement group_id="O4" value="19.86" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 3B</title>
        <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value. The serial blood samples were assessed at specified timepoints.</description>
        <time_frame>Pre-dose, 0.5 hours, 1, 1.5, 2, 2.5, 4, 8, 12, 24, 36, 48, and 72 hours postdose</time_frame>
        <population>PK parameter Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma t1/2 for Ambrisentan and Tadalafil in FDC and Reference Treatment Under Fed and Fasted Condition- Part 3B</title>
          <description>t1/2 is defined as the time required by the concentration of the drug to reach half of its original value. The serial blood samples were assessed at specified timepoints.</description>
          <population>PK parameter Population.</population>
          <units>Hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ambrisentan, t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.39" spread="21.6"/>
                    <measurement group_id="O2" value="16.42" spread="17.1"/>
                    <measurement group_id="O3" value="16.15" spread="18.7"/>
                    <measurement group_id="O4" value="16.00" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tadalafil, t1/2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.27" spread="34.3"/>
                    <measurement group_id="O2" value="19.01" spread="31.1"/>
                    <measurement group_id="O3" value="20.34" spread="34.4"/>
                    <measurement group_id="O4" value="18.95" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), Part 1</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP and DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1. Safety population included all the participants enrolled into the study who received atleast one dose of investigational product.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital- Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP), Part 1</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP and DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1. Safety population included all the participants enrolled into the study who received atleast one dose of investigational product.</description>
          <population>Safety Population</population>
          <units>Milliliters of Mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.33" spread="6.626"/>
                    <measurement group_id="O2" value="-3.54" spread="4.164"/>
                    <measurement group_id="O3" value="-4.20" spread="5.622"/>
                    <measurement group_id="O4" value="-2.86" spread="5.330"/>
                    <measurement group_id="O5" value="-2.79" spread="7.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.33" spread="6.516"/>
                    <measurement group_id="O2" value="-4.72" spread="4.008"/>
                    <measurement group_id="O3" value="-5.63" spread="3.938"/>
                    <measurement group_id="O4" value="-5.73" spread="6.001"/>
                    <measurement group_id="O5" value="-4.40" spread="4.705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.24" spread="7.118"/>
                    <measurement group_id="O2" value="-5.28" spread="5.220"/>
                    <measurement group_id="O3" value="-5.98" spread="3.632"/>
                    <measurement group_id="O4" value="-7.27" spread="5.101"/>
                    <measurement group_id="O5" value="-5.83" spread="4.856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.29" spread="5.205"/>
                    <measurement group_id="O2" value="-5.72" spread="4.064"/>
                    <measurement group_id="O3" value="-6.07" spread="6.031"/>
                    <measurement group_id="O4" value="-7.09" spread="5.149"/>
                    <measurement group_id="O5" value="-5.21" spread="6.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.10" spread="9.963"/>
                    <measurement group_id="O2" value="-6.67" spread="6.704"/>
                    <measurement group_id="O3" value="-6.50" spread="5.610"/>
                    <measurement group_id="O4" value="-9.68" spread="6.263"/>
                    <measurement group_id="O5" value="-7.83" spread="6.487"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.76" spread="7.604"/>
                    <measurement group_id="O2" value="-6.16" spread="5.685"/>
                    <measurement group_id="O3" value="-5.72" spread="5.994"/>
                    <measurement group_id="O4" value="-8.18" spread="8.296"/>
                    <measurement group_id="O5" value="-5.60" spread="7.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.86" spread="7.004"/>
                    <measurement group_id="O2" value="-4.50" spread="6.308"/>
                    <measurement group_id="O3" value="-4.07" spread="5.792"/>
                    <measurement group_id="O4" value="-5.59" spread="6.235"/>
                    <measurement group_id="O5" value="-3.55" spread="5.987"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.38" spread="5.232"/>
                    <measurement group_id="O2" value="-1.02" spread="6.091"/>
                    <measurement group_id="O3" value="-4.02" spread="6.589"/>
                    <measurement group_id="O4" value="-4.18" spread="4.382"/>
                    <measurement group_id="O5" value="-0.74" spread="6.644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.76" spread="5.845"/>
                    <measurement group_id="O2" value="-0.67" spread="5.676"/>
                    <measurement group_id="O3" value="0.20" spread="7.371"/>
                    <measurement group_id="O4" value="-1.73" spread="5.311"/>
                    <measurement group_id="O5" value="-0.15" spread="6.556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="7.521"/>
                    <measurement group_id="O2" value="-3.22" spread="8.590"/>
                    <measurement group_id="O3" value="-1.59" spread="5.441"/>
                    <measurement group_id="O4" value="-3.68" spread="6.438"/>
                    <measurement group_id="O5" value="-3.36" spread="4.953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" spread="8.153"/>
                    <measurement group_id="O2" value="-4.13" spread="7.091"/>
                    <measurement group_id="O3" value="-2.54" spread="7.662"/>
                    <measurement group_id="O4" value="-6.00" spread="7.624"/>
                    <measurement group_id="O5" value="-3.74" spread="6.549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.05" spread="9.822"/>
                    <measurement group_id="O2" value="-5.39" spread="7.116"/>
                    <measurement group_id="O3" value="-3.11" spread="6.098"/>
                    <measurement group_id="O4" value="-6.91" spread="9.148"/>
                    <measurement group_id="O5" value="-5.40" spread="4.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.90" spread="7.143"/>
                    <measurement group_id="O2" value="-7.30" spread="8.244"/>
                    <measurement group_id="O3" value="-5.50" spread="5.671"/>
                    <measurement group_id="O4" value="-6.59" spread="7.699"/>
                    <measurement group_id="O5" value="-5.36" spread="7.892"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.10" spread="8.770"/>
                    <measurement group_id="O2" value="-5.48" spread="9.279"/>
                    <measurement group_id="O3" value="-4.02" spread="7.346"/>
                    <measurement group_id="O4" value="-10.55" spread="9.579"/>
                    <measurement group_id="O5" value="-8.40" spread="8.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="8.755"/>
                    <measurement group_id="O2" value="-0.84" spread="9.278"/>
                    <measurement group_id="O3" value="0.54" spread="9.720"/>
                    <measurement group_id="O4" value="-4.77" spread="12.023"/>
                    <measurement group_id="O5" value="-3.60" spread="8.185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="6.541"/>
                    <measurement group_id="O2" value="-3.17" spread="9.767"/>
                    <measurement group_id="O3" value="0.02" spread="7.770"/>
                    <measurement group_id="O4" value="-3.82" spread="7.276"/>
                    <measurement group_id="O5" value="-1.79" spread="6.758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="9.052"/>
                    <measurement group_id="O2" value="2.39" spread="7.010"/>
                    <measurement group_id="O3" value="2.50" spread="8.577"/>
                    <measurement group_id="O4" value="-0.64" spread="7.315"/>
                    <measurement group_id="O5" value="-0.31" spread="8.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" spread="7.048"/>
                    <measurement group_id="O2" value="3.52" spread="8.993"/>
                    <measurement group_id="O3" value="3.37" spread="8.801"/>
                    <measurement group_id="O4" value="4.18" spread="7.341"/>
                    <measurement group_id="O5" value="3.00" spread="7.854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs-Heart Rate, Part 1</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Heart rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs-Heart Rate, Part 1</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Heart rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="4.766"/>
                    <measurement group_id="O2" value="2.89" spread="2.558"/>
                    <measurement group_id="O3" value="1.13" spread="3.181"/>
                    <measurement group_id="O4" value="2.98" spread="3.718"/>
                    <measurement group_id="O5" value="3.74" spread="4.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" spread="4.314"/>
                    <measurement group_id="O2" value="4.11" spread="2.620"/>
                    <measurement group_id="O3" value="2.48" spread="4.981"/>
                    <measurement group_id="O4" value="3.30" spread="3.112"/>
                    <measurement group_id="O5" value="4.17" spread="4.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="5.451"/>
                    <measurement group_id="O2" value="4.41" spread="3.107"/>
                    <measurement group_id="O3" value="1.91" spread="4.562"/>
                    <measurement group_id="O4" value="2.48" spread="4.393"/>
                    <measurement group_id="O5" value="2.83" spread="4.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="4.449"/>
                    <measurement group_id="O2" value="3.63" spread="3.331"/>
                    <measurement group_id="O3" value="1.52" spread="4.636"/>
                    <measurement group_id="O4" value="3.16" spread="5.176"/>
                    <measurement group_id="O5" value="2.12" spread="3.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.26" spread="6.488"/>
                    <measurement group_id="O2" value="7.93" spread="5.407"/>
                    <measurement group_id="O3" value="7.17" spread="6.583"/>
                    <measurement group_id="O4" value="6.11" spread="5.323"/>
                    <measurement group_id="O5" value="7.55" spread="5.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.40" spread="6.387"/>
                    <measurement group_id="O2" value="12.75" spread="6.141"/>
                    <measurement group_id="O3" value="10.48" spread="7.264"/>
                    <measurement group_id="O4" value="11.11" spread="7.687"/>
                    <measurement group_id="O5" value="10.83" spread="5.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="4.498"/>
                    <measurement group_id="O2" value="7.02" spread="6.343"/>
                    <measurement group_id="O3" value="6.52" spread="5.371"/>
                    <measurement group_id="O4" value="5.61" spread="5.381"/>
                    <measurement group_id="O5" value="6.74" spread="7.915"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.21" spread="5.110"/>
                    <measurement group_id="O2" value="8.67" spread="6.539"/>
                    <measurement group_id="O3" value="7.57" spread="5.623"/>
                    <measurement group_id="O4" value="6.48" spread="5.302"/>
                    <measurement group_id="O5" value="7.69" spread="5.501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21" spread="4.665"/>
                    <measurement group_id="O2" value="7.54" spread="7.762"/>
                    <measurement group_id="O3" value="6.57" spread="7.789"/>
                    <measurement group_id="O4" value="5.57" spread="7.323"/>
                    <measurement group_id="O5" value="5.03" spread="6.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital- Temperature, Part 1</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital- Temperature, Part 1</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population</population>
          <units>Degree celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.220"/>
                    <measurement group_id="O2" value="-0.05" spread="0.250"/>
                    <measurement group_id="O3" value="-0.12" spread="0.233"/>
                    <measurement group_id="O4" value="-0.18" spread="0.357"/>
                    <measurement group_id="O5" value="-0.03" spread="0.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.275"/>
                    <measurement group_id="O2" value="-0.09" spread="0.343"/>
                    <measurement group_id="O3" value="-0.07" spread="0.216"/>
                    <measurement group_id="O4" value="-0.06" spread="0.426"/>
                    <measurement group_id="O5" value="-0.12" spread="0.386"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.271"/>
                    <measurement group_id="O2" value="-0.16" spread="0.383"/>
                    <measurement group_id="O3" value="-0.23" spread="0.392"/>
                    <measurement group_id="O4" value="-0.04" spread="0.473"/>
                    <measurement group_id="O5" value="-0.14" spread="0.393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.363"/>
                    <measurement group_id="O2" value="-0.08" spread="0.326"/>
                    <measurement group_id="O3" value="-0.17" spread="0.328"/>
                    <measurement group_id="O4" value="-0.03" spread="0.331"/>
                    <measurement group_id="O5" value="-0.10" spread="0.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.460"/>
                    <measurement group_id="O2" value="0.03" spread="0.438"/>
                    <measurement group_id="O3" value="-0.08" spread="0.400"/>
                    <measurement group_id="O4" value="0.08" spread="0.422"/>
                    <measurement group_id="O5" value="0.02" spread="0.408"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.371"/>
                    <measurement group_id="O2" value="0.16" spread="0.386"/>
                    <measurement group_id="O3" value="-0.03" spread="0.438"/>
                    <measurement group_id="O4" value="0.08" spread="0.405"/>
                    <measurement group_id="O5" value="0.02" spread="0.597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.273"/>
                    <measurement group_id="O2" value="0.03" spread="0.328"/>
                    <measurement group_id="O3" value="0.14" spread="0.390"/>
                    <measurement group_id="O4" value="0.13" spread="0.413"/>
                    <measurement group_id="O5" value="0.07" spread="0.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.371"/>
                    <measurement group_id="O2" value="0.18" spread="0.404"/>
                    <measurement group_id="O3" value="0.01" spread="0.393"/>
                    <measurement group_id="O4" value="0.05" spread="0.571"/>
                    <measurement group_id="O5" value="0.16" spread="0.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.351"/>
                    <measurement group_id="O2" value="0.03" spread="0.503"/>
                    <measurement group_id="O3" value="-0.02" spread="0.392"/>
                    <measurement group_id="O4" value="0.10" spread="0.424"/>
                    <measurement group_id="O5" value="0.02" spread="0.506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs-Respiratory Rate, Part 1</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs-Respiratory Rate, Part 1</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Respiratory rate, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.23"/>
                    <measurement group_id="O2" value="-0.7" spread="2.38"/>
                    <measurement group_id="O3" value="-0.1" spread="3.17"/>
                    <measurement group_id="O4" value="0.3" spread="1.88"/>
                    <measurement group_id="O5" value="1.1" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.62"/>
                    <measurement group_id="O2" value="-1.0" spread="2.69"/>
                    <measurement group_id="O3" value="0.0" spread="2.76"/>
                    <measurement group_id="O4" value="0.6" spread="2.72"/>
                    <measurement group_id="O5" value="0.6" spread="2.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="1.56"/>
                    <measurement group_id="O2" value="-1.0" spread="2.08"/>
                    <measurement group_id="O3" value="-0.2" spread="2.55"/>
                    <measurement group_id="O4" value="0.4" spread="2.48"/>
                    <measurement group_id="O5" value="0.5" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="2.10"/>
                    <measurement group_id="O2" value="-0.8" spread="1.98"/>
                    <measurement group_id="O3" value="-0.5" spread="2.91"/>
                    <measurement group_id="O4" value="0.2" spread="2.54"/>
                    <measurement group_id="O5" value="0.4" spread="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.73"/>
                    <measurement group_id="O2" value="0.2" spread="2.33"/>
                    <measurement group_id="O3" value="0.0" spread="2.63"/>
                    <measurement group_id="O4" value="0.6" spread="2.42"/>
                    <measurement group_id="O5" value="0.6" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.86"/>
                    <measurement group_id="O2" value="0.4" spread="1.81"/>
                    <measurement group_id="O3" value="0.3" spread="2.93"/>
                    <measurement group_id="O4" value="0.9" spread="2.94"/>
                    <measurement group_id="O5" value="1.7" spread="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.44"/>
                    <measurement group_id="O2" value="-0.7" spread="2.22"/>
                    <measurement group_id="O3" value="-0.4" spread="2.63"/>
                    <measurement group_id="O4" value="-0.1" spread="2.35"/>
                    <measurement group_id="O5" value="1.0" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.68"/>
                    <measurement group_id="O2" value="-0.6" spread="2.52"/>
                    <measurement group_id="O3" value="0.4" spread="3.07"/>
                    <measurement group_id="O4" value="-0.0" spread="2.55"/>
                    <measurement group_id="O5" value="0.3" spread="3.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.44"/>
                    <measurement group_id="O2" value="-0.1" spread="3.38"/>
                    <measurement group_id="O3" value="0.7" spread="3.17"/>
                    <measurement group_id="O4" value="1.0" spread="2.60"/>
                    <measurement group_id="O5" value="0.8" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital- SBP and DBP, Part 2</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP and DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital- SBP and DBP, Part 2</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP and DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population</population>
          <units>Milliliters of Mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" spread="5.396"/>
                    <measurement group_id="O2" value="0.28" spread="5.707"/>
                    <measurement group_id="O3" value="-0.25" spread="5.564"/>
                    <measurement group_id="O4" value="-1.00" spread="5.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.71" spread="7.329"/>
                    <measurement group_id="O2" value="-4.23" spread="5.686"/>
                    <measurement group_id="O3" value="-4.55" spread="5.264"/>
                    <measurement group_id="O4" value="-4.35" spread="5.703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.67" spread="7.073"/>
                    <measurement group_id="O2" value="-4.98" spread="5.488"/>
                    <measurement group_id="O3" value="-5.85" spread="5.974"/>
                    <measurement group_id="O4" value="-7.05" spread="5.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="6.468"/>
                    <measurement group_id="O2" value="-3.53" spread="7.159"/>
                    <measurement group_id="O3" value="-3.90" spread="7.080"/>
                    <measurement group_id="O4" value="-5.10" spread="6.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.43" spread="8.603"/>
                    <measurement group_id="O2" value="-2.58" spread="7.979"/>
                    <measurement group_id="O3" value="-5.15" spread="6.917"/>
                    <measurement group_id="O4" value="-5.65" spread="8.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.76" spread="7.800"/>
                    <measurement group_id="O2" value="-3.18" spread="5.669"/>
                    <measurement group_id="O3" value="-2.25" spread="6.084"/>
                    <measurement group_id="O4" value="-4.35" spread="5.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.00" spread="7.342"/>
                    <measurement group_id="O2" value="-1.03" spread="6.791"/>
                    <measurement group_id="O3" value="-2.00" spread="6.318"/>
                    <measurement group_id="O4" value="-5.25" spread="6.470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.29" spread="7.125"/>
                    <measurement group_id="O2" value="2.48" spread="6.451"/>
                    <measurement group_id="O3" value="1.35" spread="5.956"/>
                    <measurement group_id="O4" value="1.40" spread="4.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95" spread="8.399"/>
                    <measurement group_id="O2" value="3.23" spread="5.357"/>
                    <measurement group_id="O3" value="2.05" spread="6.671"/>
                    <measurement group_id="O4" value="1.50" spread="6.907"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.57" spread="5.388"/>
                    <measurement group_id="O2" value="1.63" spread="5.314"/>
                    <measurement group_id="O3" value="2.90" spread="4.576"/>
                    <measurement group_id="O4" value="-0.33" spread="4.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.43" spread="8.996"/>
                    <measurement group_id="O2" value="-3.93" spread="6.057"/>
                    <measurement group_id="O3" value="-2.05" spread="8.000"/>
                    <measurement group_id="O4" value="-1.98" spread="7.144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.52" spread="8.848"/>
                    <measurement group_id="O2" value="-2.48" spread="5.683"/>
                    <measurement group_id="O3" value="-1.45" spread="7.112"/>
                    <measurement group_id="O4" value="-7.33" spread="9.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="7.561"/>
                    <measurement group_id="O2" value="-2.13" spread="6.456"/>
                    <measurement group_id="O3" value="-2.45" spread="7.082"/>
                    <measurement group_id="O4" value="-5.58" spread="6.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.43" spread="8.982"/>
                    <measurement group_id="O2" value="-3.98" spread="7.046"/>
                    <measurement group_id="O3" value="-2.35" spread="6.471"/>
                    <measurement group_id="O4" value="-6.38" spread="8.617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" spread="7.292"/>
                    <measurement group_id="O2" value="4.38" spread="9.418"/>
                    <measurement group_id="O3" value="2.00" spread="6.951"/>
                    <measurement group_id="O4" value="0.83" spread="6.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.95" spread="7.847"/>
                    <measurement group_id="O2" value="-0.68" spread="8.307"/>
                    <measurement group_id="O3" value="-0.30" spread="8.163"/>
                    <measurement group_id="O4" value="-1.68" spread="6.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="5.820"/>
                    <measurement group_id="O2" value="4.78" spread="7.911"/>
                    <measurement group_id="O3" value="0.85" spread="8.570"/>
                    <measurement group_id="O4" value="2.08" spread="4.660"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.14" spread="7.636"/>
                    <measurement group_id="O2" value="5.13" spread="7.609"/>
                    <measurement group_id="O3" value="5.00" spread="6.345"/>
                    <measurement group_id="O4" value="3.48" spread="8.367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs-Heart Rate, Part 2</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Heart rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1. Safety population included all the participants enrolled into the study who received atleast one dose of investigational product.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs-Heart Rate, Part 2</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Heart rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1. Safety population included all the participants enrolled into the study who received atleast one dose of investigational product.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="4.040"/>
                    <measurement group_id="O2" value="2.85" spread="4.934"/>
                    <measurement group_id="O3" value="1.95" spread="6.219"/>
                    <measurement group_id="O4" value="2.20" spread="3.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" spread="4.475"/>
                    <measurement group_id="O2" value="3.85" spread="4.665"/>
                    <measurement group_id="O3" value="5.10" spread="6.528"/>
                    <measurement group_id="O4" value="5.35" spread="3.208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" spread="3.720"/>
                    <measurement group_id="O2" value="3.75" spread="6.568"/>
                    <measurement group_id="O3" value="2.75" spread="5.959"/>
                    <measurement group_id="O4" value="6.45" spread="6.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.36" spread="5.287"/>
                    <measurement group_id="O2" value="5.45" spread="11.978"/>
                    <measurement group_id="O3" value="3.20" spread="7.428"/>
                    <measurement group_id="O4" value="6.00" spread="5.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.36" spread="7.720"/>
                    <measurement group_id="O2" value="8.30" spread="7.596"/>
                    <measurement group_id="O3" value="6.55" spread="6.901"/>
                    <measurement group_id="O4" value="8.30" spread="9.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.21" spread="7.348"/>
                    <measurement group_id="O2" value="14.80" spread="9.512"/>
                    <measurement group_id="O3" value="15.50" spread="6.473"/>
                    <measurement group_id="O4" value="16.45" spread="6.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.74" spread="6.100"/>
                    <measurement group_id="O2" value="8.80" spread="6.031"/>
                    <measurement group_id="O3" value="8.00" spread="7.395"/>
                    <measurement group_id="O4" value="8.70" spread="7.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" spread="5.361"/>
                    <measurement group_id="O2" value="5.70" spread="4.697"/>
                    <measurement group_id="O3" value="5.10" spread="5.973"/>
                    <measurement group_id="O4" value="5.90" spread="4.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.40" spread="8.412"/>
                    <measurement group_id="O2" value="7.90" spread="8.534"/>
                    <measurement group_id="O3" value="7.80" spread="8.427"/>
                    <measurement group_id="O4" value="9.30" spread="7.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital- Temperature, Part 2</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1. Safety population included all the participants enrolled into the study who received atleast one dose of investigational product.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital- Temperature, Part 2</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1. Safety population included all the participants enrolled into the study who received atleast one dose of investigational product.</description>
          <population>Safety Population</population>
          <units>Degree celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.403"/>
                    <measurement group_id="O2" value="-0.02" spread="0.281"/>
                    <measurement group_id="O3" value="-0.05" spread="0.261"/>
                    <measurement group_id="O4" value="-0.14" spread="0.339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.280"/>
                    <measurement group_id="O2" value="-0.11" spread="0.301"/>
                    <measurement group_id="O3" value="-0.01" spread="0.300"/>
                    <measurement group_id="O4" value="-0.04" spread="0.342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.12" spread="0.349"/>
                    <measurement group_id="O2" value="-0.17" spread="0.279"/>
                    <measurement group_id="O3" value="-0.03" spread="0.310"/>
                    <measurement group_id="O4" value="-0.23" spread="0.397"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.348"/>
                    <measurement group_id="O2" value="-0.06" spread="0.366"/>
                    <measurement group_id="O3" value="0.03" spread="0.286"/>
                    <measurement group_id="O4" value="-0.19" spread="0.399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.397"/>
                    <measurement group_id="O2" value="-0.08" spread="0.375"/>
                    <measurement group_id="O3" value="0.05" spread="0.343"/>
                    <measurement group_id="O4" value="0.03" spread="0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="0.409"/>
                    <measurement group_id="O2" value="0.04" spread="0.437"/>
                    <measurement group_id="O3" value="0.09" spread="0.418"/>
                    <measurement group_id="O4" value="0.10" spread="0.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.285"/>
                    <measurement group_id="O2" value="-0.02" spread="0.373"/>
                    <measurement group_id="O3" value="0.24" spread="0.298"/>
                    <measurement group_id="O4" value="0.07" spread="0.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.441"/>
                    <measurement group_id="O2" value="-0.06" spread="0.312"/>
                    <measurement group_id="O3" value="0.03" spread="0.353"/>
                    <measurement group_id="O4" value="-0.11" spread="0.488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.435"/>
                    <measurement group_id="O2" value="-0.13" spread="0.490"/>
                    <measurement group_id="O3" value="0.05" spread="0.375"/>
                    <measurement group_id="O4" value="0.06" spread="0.366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs-Respiratory Rate, Part 2</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs-Respiratory Rate, Part 2</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Respiratory rate, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.92"/>
                    <measurement group_id="O2" value="-0.7" spread="2.27"/>
                    <measurement group_id="O3" value="0.3" spread="2.85"/>
                    <measurement group_id="O4" value="-1.1" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.15"/>
                    <measurement group_id="O2" value="-0.4" spread="2.56"/>
                    <measurement group_id="O3" value="0.3" spread="2.70"/>
                    <measurement group_id="O4" value="-0.7" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="3.32"/>
                    <measurement group_id="O2" value="-1.2" spread="2.86"/>
                    <measurement group_id="O3" value="0.4" spread="3.41"/>
                    <measurement group_id="O4" value="-1.1" spread="2.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="2.87"/>
                    <measurement group_id="O2" value="-0.1" spread="3.34"/>
                    <measurement group_id="O3" value="-0.1" spread="3.21"/>
                    <measurement group_id="O4" value="-1.0" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="3.00"/>
                    <measurement group_id="O2" value="0.5" spread="2.82"/>
                    <measurement group_id="O3" value="0.4" spread="2.37"/>
                    <measurement group_id="O4" value="-0.5" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.93"/>
                    <measurement group_id="O2" value="0.2" spread="2.46"/>
                    <measurement group_id="O3" value="0.8" spread="2.61"/>
                    <measurement group_id="O4" value="-0.5" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="3.00"/>
                    <measurement group_id="O2" value="-0.3" spread="2.92"/>
                    <measurement group_id="O3" value="1.3" spread="2.70"/>
                    <measurement group_id="O4" value="0.4" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="2.60"/>
                    <measurement group_id="O2" value="-0.2" spread="2.14"/>
                    <measurement group_id="O3" value="0.7" spread="2.62"/>
                    <measurement group_id="O4" value="-0.6" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="2.79"/>
                    <measurement group_id="O2" value="0.6" spread="2.67"/>
                    <measurement group_id="O3" value="0.6" spread="2.91"/>
                    <measurement group_id="O4" value="0.6" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital- SBP and DBP, Part 3A</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP, DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital- SBP and DBP, Part 3A</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP, DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population</population>
          <units>Milliliters of Mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.47" spread="6.724"/>
                    <measurement group_id="O2" value="-0.36" spread="5.821"/>
                    <measurement group_id="O3" value="-3.02" spread="7.779"/>
                    <measurement group_id="O4" value="-1.45" spread="6.943"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.69" spread="6.509"/>
                    <measurement group_id="O2" value="-4.73" spread="6.418"/>
                    <measurement group_id="O3" value="-5.86" spread="7.055"/>
                    <measurement group_id="O4" value="-5.36" spread="7.768"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.97" spread="7.104"/>
                    <measurement group_id="O2" value="-6.03" spread="5.840"/>
                    <measurement group_id="O3" value="-6.89" spread="6.173"/>
                    <measurement group_id="O4" value="-6.05" spread="7.745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.75" spread="5.879"/>
                    <measurement group_id="O2" value="-6.24" spread="6.148"/>
                    <measurement group_id="O3" value="-10.30" spread="6.722"/>
                    <measurement group_id="O4" value="-6.27" spread="7.799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.41" spread="7.088"/>
                    <measurement group_id="O2" value="-7.76" spread="8.100"/>
                    <measurement group_id="O3" value="-6.45" spread="8.865"/>
                    <measurement group_id="O4" value="-8.20" spread="8.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.25" spread="7.097"/>
                    <measurement group_id="O2" value="-6.18" spread="8.080"/>
                    <measurement group_id="O3" value="-7.67" spread="8.274"/>
                    <measurement group_id="O4" value="-7.36" spread="9.886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.25" spread="7.033"/>
                    <measurement group_id="O2" value="-4.27" spread="6.011"/>
                    <measurement group_id="O3" value="-4.77" spread="7.168"/>
                    <measurement group_id="O4" value="-5.89" spread="6.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.41" spread="9.414"/>
                    <measurement group_id="O2" value="-0.79" spread="7.730"/>
                    <measurement group_id="O3" value="-1.89" spread="6.945"/>
                    <measurement group_id="O4" value="-1.77" spread="7.503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="6.361"/>
                    <measurement group_id="O2" value="1.24" spread="6.544"/>
                    <measurement group_id="O3" value="-1.52" spread="9.187"/>
                    <measurement group_id="O4" value="0.80" spread="9.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" spread="5.236"/>
                    <measurement group_id="O2" value="-0.32" spread="8.074"/>
                    <measurement group_id="O3" value="4.55" spread="8.543"/>
                    <measurement group_id="O4" value="0.17" spread="5.822"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="7.478"/>
                    <measurement group_id="O2" value="-4.14" spread="9.772"/>
                    <measurement group_id="O3" value="2.86" spread="9.186"/>
                    <measurement group_id="O4" value="-1.95" spread="5.959"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="9.549"/>
                    <measurement group_id="O2" value="-2.05" spread="8.873"/>
                    <measurement group_id="O3" value="-0.08" spread="7.294"/>
                    <measurement group_id="O4" value="-3.95" spread="6.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="7.699"/>
                    <measurement group_id="O2" value="-4.35" spread="9.423"/>
                    <measurement group_id="O3" value="-4.30" spread="8.270"/>
                    <measurement group_id="O4" value="-4.77" spread="7.717"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.06" spread="9.313"/>
                    <measurement group_id="O2" value="-5.32" spread="10.608"/>
                    <measurement group_id="O3" value="-5.23" spread="9.288"/>
                    <measurement group_id="O4" value="-5.27" spread="7.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="8.372"/>
                    <measurement group_id="O2" value="-0.47" spread="10.702"/>
                    <measurement group_id="O3" value="-1.05" spread="9.116"/>
                    <measurement group_id="O4" value="-1.58" spread="9.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="8.974"/>
                    <measurement group_id="O2" value="-1.08" spread="10.400"/>
                    <measurement group_id="O3" value="-2.48" spread="6.478"/>
                    <measurement group_id="O4" value="-2.08" spread="7.106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" spread="8.437"/>
                    <measurement group_id="O2" value="1.68" spread="9.134"/>
                    <measurement group_id="O3" value="1.36" spread="7.927"/>
                    <measurement group_id="O4" value="0.80" spread="7.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="8.538"/>
                    <measurement group_id="O2" value="3.14" spread="11.277"/>
                    <measurement group_id="O3" value="3.86" spread="11.332"/>
                    <measurement group_id="O4" value="3.52" spread="6.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs-Heart Rate, Part 3A</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Heart rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs-Heart Rate, Part 3A</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Heart rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.28" spread="5.785"/>
                    <measurement group_id="O2" value="2.64" spread="3.900"/>
                    <measurement group_id="O3" value="10.66" spread="4.717"/>
                    <measurement group_id="O4" value="2.81" spread="4.156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.28" spread="6.108"/>
                    <measurement group_id="O2" value="5.52" spread="4.154"/>
                    <measurement group_id="O3" value="12.97" spread="6.573"/>
                    <measurement group_id="O4" value="4.66" spread="3.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.06" spread="5.891"/>
                    <measurement group_id="O2" value="4.61" spread="4.565"/>
                    <measurement group_id="O3" value="11.41" spread="6.439"/>
                    <measurement group_id="O4" value="4.16" spread="4.306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.16" spread="6.491"/>
                    <measurement group_id="O2" value="5.06" spread="6.910"/>
                    <measurement group_id="O3" value="10.91" spread="5.431"/>
                    <measurement group_id="O4" value="4.44" spread="4.629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.06" spread="5.872"/>
                    <measurement group_id="O2" value="10.79" spread="7.847"/>
                    <measurement group_id="O3" value="10.16" spread="7.407"/>
                    <measurement group_id="O4" value="8.56" spread="6.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.28" spread="10.232"/>
                    <measurement group_id="O2" value="15.91" spread="9.669"/>
                    <measurement group_id="O3" value="14.38" spread="10.204"/>
                    <measurement group_id="O4" value="16.38" spread="8.917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.72" spread="5.341"/>
                    <measurement group_id="O2" value="8.73" spread="7.048"/>
                    <measurement group_id="O3" value="7.00" spread="6.673"/>
                    <measurement group_id="O4" value="7.28" spread="4.704"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.50" spread="4.465"/>
                    <measurement group_id="O2" value="9.45" spread="7.527"/>
                    <measurement group_id="O3" value="9.47" spread="7.301"/>
                    <measurement group_id="O4" value="8.03" spread="5.290"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.19" spread="6.708"/>
                    <measurement group_id="O2" value="10.91" spread="10.476"/>
                    <measurement group_id="O3" value="9.59" spread="9.088"/>
                    <measurement group_id="O4" value="10.03" spread="8.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital- Temperature, Part 3A</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital- Temperature, Part 3A</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.288"/>
                    <measurement group_id="O2" value="0.01" spread="0.344"/>
                    <measurement group_id="O3" value="0.15" spread="0.306"/>
                    <measurement group_id="O4" value="0.12" spread="0.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.252"/>
                    <measurement group_id="O2" value="0.07" spread="0.315"/>
                    <measurement group_id="O3" value="0.12" spread="0.262"/>
                    <measurement group_id="O4" value="0.04" spread="0.282"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.278"/>
                    <measurement group_id="O2" value="0.05" spread="0.268"/>
                    <measurement group_id="O3" value="0.10" spread="0.244"/>
                    <measurement group_id="O4" value="0.07" spread="0.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.352"/>
                    <measurement group_id="O2" value="0.15" spread="0.299"/>
                    <measurement group_id="O3" value="0.16" spread="0.305"/>
                    <measurement group_id="O4" value="-0.01" spread="0.402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.450"/>
                    <measurement group_id="O2" value="0.12" spread="0.425"/>
                    <measurement group_id="O3" value="0.15" spread="0.409"/>
                    <measurement group_id="O4" value="0.15" spread="0.504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22" spread="0.409"/>
                    <measurement group_id="O2" value="0.27" spread="0.392"/>
                    <measurement group_id="O3" value="0.09" spread="0.366"/>
                    <measurement group_id="O4" value="0.27" spread="0.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.429"/>
                    <measurement group_id="O2" value="0.25" spread="0.351"/>
                    <measurement group_id="O3" value="0.06" spread="0.332"/>
                    <measurement group_id="O4" value="0.16" spread="0.362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.713"/>
                    <measurement group_id="O2" value="0.28" spread="0.473"/>
                    <measurement group_id="O3" value="0.12" spread="0.358"/>
                    <measurement group_id="O4" value="0.32" spread="0.327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.414"/>
                    <measurement group_id="O2" value="0.20" spread="0.334"/>
                    <measurement group_id="O3" value="0.10" spread="0.418"/>
                    <measurement group_id="O4" value="0.18" spread="0.520"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs-Respiratory Rate, Part 3A</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs-Respiratory Rate, Part 3A</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Respiratory rate, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.51"/>
                    <measurement group_id="O2" value="0.8" spread="1.95"/>
                    <measurement group_id="O3" value="1.5" spread="2.66"/>
                    <measurement group_id="O4" value="-0.2" spread="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.83"/>
                    <measurement group_id="O2" value="0.2" spread="2.57"/>
                    <measurement group_id="O3" value="0.8" spread="2.26"/>
                    <measurement group_id="O4" value="-0.7" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="2.72"/>
                    <measurement group_id="O2" value="0.7" spread="2.59"/>
                    <measurement group_id="O3" value="0.6" spread="2.30"/>
                    <measurement group_id="O4" value="0.2" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.76"/>
                    <measurement group_id="O2" value="0.2" spread="2.21"/>
                    <measurement group_id="O3" value="1.1" spread="2.59"/>
                    <measurement group_id="O4" value="0.1" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="2.85"/>
                    <measurement group_id="O2" value="0.1" spread="2.15"/>
                    <measurement group_id="O3" value="0.5" spread="2.49"/>
                    <measurement group_id="O4" value="-0.3" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="3.21"/>
                    <measurement group_id="O2" value="0.5" spread="2.33"/>
                    <measurement group_id="O3" value="0.6" spread="2.97"/>
                    <measurement group_id="O4" value="0.4" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="3.14"/>
                    <measurement group_id="O2" value="0.1" spread="2.26"/>
                    <measurement group_id="O3" value="0.2" spread="2.75"/>
                    <measurement group_id="O4" value="-1.3" spread="2.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="2.03"/>
                    <measurement group_id="O2" value="-0.1" spread="2.45"/>
                    <measurement group_id="O3" value="0.6" spread="2.93"/>
                    <measurement group_id="O4" value="-0.7" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.79"/>
                    <measurement group_id="O2" value="0.3" spread="3.05"/>
                    <measurement group_id="O3" value="0.8" spread="1.96"/>
                    <measurement group_id="O4" value="0.1" spread="2.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital- SBP and DBP, Part 3B</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP and DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital- SBP and DBP, Part 3B</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for SBP and DBP. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population.</population>
          <units>Milliliters of Mercury</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DBP, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.42" spread="6.365"/>
                    <measurement group_id="O2" value="-2.15" spread="6.582"/>
                    <measurement group_id="O3" value="-2.53" spread="5.507"/>
                    <measurement group_id="O4" value="-1.53" spread="6.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.92" spread="6.443"/>
                    <measurement group_id="O2" value="-3.31" spread="5.569"/>
                    <measurement group_id="O3" value="-3.41" spread="7.157"/>
                    <measurement group_id="O4" value="-3.73" spread="6.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.52" spread="10.758"/>
                    <measurement group_id="O2" value="-5.92" spread="6.044"/>
                    <measurement group_id="O3" value="-5.00" spread="5.651"/>
                    <measurement group_id="O4" value="-5.70" spread="5.842"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.02" spread="4.481"/>
                    <measurement group_id="O2" value="-6.85" spread="5.455"/>
                    <measurement group_id="O3" value="-6.56" spread="6.488"/>
                    <measurement group_id="O4" value="-6.80" spread="6.884"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.38" spread="8.616"/>
                    <measurement group_id="O2" value="-6.56" spread="5.815"/>
                    <measurement group_id="O3" value="-7.81" spread="6.258"/>
                    <measurement group_id="O4" value="-7.23" spread="9.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.38" spread="8.189"/>
                    <measurement group_id="O2" value="-5.15" spread="6.431"/>
                    <measurement group_id="O3" value="-5.88" spread="6.644"/>
                    <measurement group_id="O4" value="-7.57" spread="6.494"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" spread="6.464"/>
                    <measurement group_id="O2" value="-4.05" spread="6.571"/>
                    <measurement group_id="O3" value="-3.31" spread="5.118"/>
                    <measurement group_id="O4" value="-4.90" spread="5.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="7.945"/>
                    <measurement group_id="O2" value="-0.40" spread="6.512"/>
                    <measurement group_id="O3" value="-0.41" spread="5.491"/>
                    <measurement group_id="O4" value="-1.50" spread="7.405"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="7.594"/>
                    <measurement group_id="O2" value="0.31" spread="4.790"/>
                    <measurement group_id="O3" value="-0.47" spread="6.074"/>
                    <measurement group_id="O4" value="-0.93" spread="6.781"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="9.323"/>
                    <measurement group_id="O2" value="-0.92" spread="8.734"/>
                    <measurement group_id="O3" value="0.30" spread="8.287"/>
                    <measurement group_id="O4" value="0.43" spread="5.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.27" spread="8.463"/>
                    <measurement group_id="O2" value="0.11" spread="8.945"/>
                    <measurement group_id="O3" value="-0.20" spread="7.893"/>
                    <measurement group_id="O4" value="0.17" spread="6.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="9.657"/>
                    <measurement group_id="O2" value="-4.34" spread="10.254"/>
                    <measurement group_id="O3" value="-1.98" spread="7.925"/>
                    <measurement group_id="O4" value="-1.10" spread="4.845"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.17" spread="8.680"/>
                    <measurement group_id="O2" value="-3.92" spread="7.959"/>
                    <measurement group_id="O3" value="-3.14" spread="5.501"/>
                    <measurement group_id="O4" value="-5.60" spread="7.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.87" spread="10.059"/>
                    <measurement group_id="O2" value="-2.95" spread="11.644"/>
                    <measurement group_id="O3" value="-3.05" spread="8.804"/>
                    <measurement group_id="O4" value="-5.03" spread="7.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="11.075"/>
                    <measurement group_id="O2" value="0.11" spread="13.298"/>
                    <measurement group_id="O3" value="0.45" spread="7.846"/>
                    <measurement group_id="O4" value="-1.03" spread="10.562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="8.805"/>
                    <measurement group_id="O2" value="-2.56" spread="8.996"/>
                    <measurement group_id="O3" value="0.36" spread="5.210"/>
                    <measurement group_id="O4" value="-1.77" spread="8.458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.33" spread="8.963"/>
                    <measurement group_id="O2" value="0.50" spread="8.748"/>
                    <measurement group_id="O3" value="3.45" spread="6.139"/>
                    <measurement group_id="O4" value="1.87" spread="8.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="9.174"/>
                    <measurement group_id="O2" value="1.76" spread="8.922"/>
                    <measurement group_id="O3" value="2.76" spread="7.236"/>
                    <measurement group_id="O4" value="1.70" spread="9.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs-Heart Rate, Part 3B</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for HR. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs-Heart Rate, Part 3B</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for HR. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HR, 0.5 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" spread="5.103"/>
                    <measurement group_id="O2" value="3.50" spread="4.911"/>
                    <measurement group_id="O3" value="2.61" spread="4.652"/>
                    <measurement group_id="O4" value="2.78" spread="4.928"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="5.784"/>
                    <measurement group_id="O2" value="4.92" spread="5.496"/>
                    <measurement group_id="O3" value="5.70" spread="4.621"/>
                    <measurement group_id="O4" value="5.48" spread="7.515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 2 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.08" spread="5.706"/>
                    <measurement group_id="O2" value="3.76" spread="5.524"/>
                    <measurement group_id="O3" value="5.67" spread="4.148"/>
                    <measurement group_id="O4" value="5.58" spread="7.157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 4 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.85" spread="6.498"/>
                    <measurement group_id="O2" value="3.69" spread="7.253"/>
                    <measurement group_id="O3" value="4.95" spread="5.564"/>
                    <measurement group_id="O4" value="6.22" spread="4.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 8 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.65" spread="8.102"/>
                    <measurement group_id="O2" value="7.34" spread="6.462"/>
                    <measurement group_id="O3" value="7.23" spread="6.453"/>
                    <measurement group_id="O4" value="8.78" spread="8.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 12 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.85" spread="9.232"/>
                    <measurement group_id="O2" value="15.50" spread="6.925"/>
                    <measurement group_id="O3" value="13.89" spread="7.574"/>
                    <measurement group_id="O4" value="16.62" spread="7.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 24 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.02" spread="6.086"/>
                    <measurement group_id="O2" value="6.92" spread="6.162"/>
                    <measurement group_id="O3" value="7.77" spread="6.677"/>
                    <measurement group_id="O4" value="7.72" spread="5.700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.72" spread="5.845"/>
                    <measurement group_id="O2" value="8.18" spread="6.657"/>
                    <measurement group_id="O3" value="8.08" spread="6.610"/>
                    <measurement group_id="O4" value="10.15" spread="9.207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HR, 72 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.78" spread="8.397"/>
                    <measurement group_id="O2" value="9.18" spread="7.853"/>
                    <measurement group_id="O3" value="7.37" spread="7.256"/>
                    <measurement group_id="O4" value="9.62" spread="7.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital- Temperature, Part 3B</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital- Temperature, Part 3B</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for temperature. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population</population>
          <units>Degree Celsius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature, 0.5 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.239"/>
                    <measurement group_id="O2" value="0.13" spread="0.329"/>
                    <measurement group_id="O3" value="0.11" spread="0.404"/>
                    <measurement group_id="O4" value="0.05" spread="0.256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 1 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.275"/>
                    <measurement group_id="O2" value="0.07" spread="0.290"/>
                    <measurement group_id="O3" value="0.10" spread="0.330"/>
                    <measurement group_id="O4" value="0.09" spread="0.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 2 hour (n=29,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.341"/>
                    <measurement group_id="O2" value="0.07" spread="0.330"/>
                    <measurement group_id="O3" value="0.09" spread="0.316"/>
                    <measurement group_id="O4" value="0.04" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 4 hour(n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.371"/>
                    <measurement group_id="O2" value="0.05" spread="0.385"/>
                    <measurement group_id="O3" value="0.07" spread="0.430"/>
                    <measurement group_id="O4" value="0.09" spread="0.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 8 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.497"/>
                    <measurement group_id="O2" value="0.22" spread="0.419"/>
                    <measurement group_id="O3" value="0.23" spread="0.456"/>
                    <measurement group_id="O4" value="0.17" spread="0.502"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 12 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.470"/>
                    <measurement group_id="O2" value="0.39" spread="0.358"/>
                    <measurement group_id="O3" value="0.32" spread="0.463"/>
                    <measurement group_id="O4" value="0.45" spread="0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 24 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.34" spread="0.347"/>
                    <measurement group_id="O2" value="0.12" spread="0.453"/>
                    <measurement group_id="O3" value="0.23" spread="0.352"/>
                    <measurement group_id="O4" value="0.19" spread="0.420"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 48 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.448"/>
                    <measurement group_id="O2" value="0.13" spread="0.424"/>
                    <measurement group_id="O3" value="0.16" spread="0.456"/>
                    <measurement group_id="O4" value="0.22" spread="0.444"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature, 72 hour (n=30,31,31,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="0.422"/>
                    <measurement group_id="O2" value="0.26" spread="0.446"/>
                    <measurement group_id="O3" value="0.14" spread="0.450"/>
                    <measurement group_id="O4" value="0.08" spread="0.377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Vital Signs-Respiratory Rate, Part 3-B</title>
        <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
        <time_frame>Baseline and Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Vital Signs-Respiratory Rate, Part 3-B</title>
          <description>Vital signs were measured in semi-supine position after 5 minutes rest and were assessed for Respiratory rate. Change from Baseline, was defined as value at post-Baseline visit minus the Baseline value. Baseline, was defined as Day 1.</description>
          <population>Safety Population.</population>
          <units>Breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Respiratory rate, 0.5 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="2.78"/>
                    <measurement group_id="O2" value="0.4" spread="2.99"/>
                    <measurement group_id="O3" value="-0.8" spread="3.08"/>
                    <measurement group_id="O4" value="0.8" spread="3.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 1 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="2.88"/>
                    <measurement group_id="O2" value="-0.7" spread="3.08"/>
                    <measurement group_id="O3" value="-0.1" spread="2.98"/>
                    <measurement group_id="O4" value="0.2" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 2 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2" spread="2.93"/>
                    <measurement group_id="O2" value="0.6" spread="3.64"/>
                    <measurement group_id="O3" value="-0.1" spread="3.20"/>
                    <measurement group_id="O4" value="0.6" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 4 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="2.68"/>
                    <measurement group_id="O2" value="0.1" spread="3.47"/>
                    <measurement group_id="O3" value="-0.4" spread="2.85"/>
                    <measurement group_id="O4" value="0.5" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 8 hour(n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="2.50"/>
                    <measurement group_id="O2" value="0.9" spread="3.31"/>
                    <measurement group_id="O3" value="0.0" spread="3.41"/>
                    <measurement group_id="O4" value="0.5" spread="2.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 12 hour (n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.67"/>
                    <measurement group_id="O2" value="-0.3" spread="2.82"/>
                    <measurement group_id="O3" value="0.2" spread="2.96"/>
                    <measurement group_id="O4" value="1.1" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 24 hour(n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.29"/>
                    <measurement group_id="O2" value="-0.7" spread="3.08"/>
                    <measurement group_id="O3" value="-0.6" spread="2.50"/>
                    <measurement group_id="O4" value="0.1" spread="3.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 48 hour(n=30,31,32,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8" spread="2.81"/>
                    <measurement group_id="O2" value="-0.0" spread="3.35"/>
                    <measurement group_id="O3" value="-0.1" spread="3.15"/>
                    <measurement group_id="O4" value="1.2" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory rate, 72 hour (n=30,31,31,30)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="31"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="3.73"/>
                    <measurement group_id="O2" value="-0.0" spread="2.95"/>
                    <measurement group_id="O3" value="0.2" spread="2.89"/>
                    <measurement group_id="O4" value="0.6" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings, -Part 1</title>
        <description>12-lead ECG, was measured in semi-supine position after 5 minutes rest. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
        <time_frame>Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Electrocardiogram (ECG) Findings, -Part 1</title>
          <description>12-lead ECG, was measured in semi-supine position after 5 minutes rest. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal ECG Findings, -Part 2</title>
        <description>12-lead ECG, were measured in semi-supine position after 5 minutes rest. It was conducted as triplicate at screen and baseline, whereas single measure at other times, unless out of range then triplicates were performed. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
        <time_frame>Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal ECG Findings, -Part 2</title>
          <description>12-lead ECG, were measured in semi-supine position after 5 minutes rest. It was conducted as triplicate at screen and baseline, whereas single measure at other times, unless out of range then triplicates were performed. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal ECG Findings, -Part 3A</title>
        <description>12-lead ECG, were measured in semi-supine position after 5 minutes rest. It was conducted as triplicate at screen and baseline, whereas single measure at other times, unless out of range then triplicates were performed. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
        <time_frame>Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal ECG Findings, -Part 3A</title>
          <description>12-lead ECG, were measured in semi-supine position after 5 minutes rest. It was conducted as triplicate at screen and baseline, whereas single measure at other times, unless out of range then triplicates were performed. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal ECG Findings, -Part 3B</title>
        <description>12-lead ECG, were measured in semi-supine position after 5 minutes rest. It was conducted as triplicate at screen and baseline, whereas single measure at other times, unless out of range then triplicates were performed. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
        <time_frame>Up to Day 3</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal ECG Findings, -Part 3B</title>
          <description>12-lead ECG, were measured in semi-supine position after 5 minutes rest. It was conducted as triplicate at screen and baseline, whereas single measure at other times, unless out of range then triplicates were performed. The data for worst case post-baseline has been reported. Data values for the participants with abnormal clinically significant values are reported. Safety population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Values of Potential Clinical Importance (PCI)- Part1</title>
        <description>Blood samples were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
        <time_frame>Up to Day 3</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg Sodium laurilsulfate (SLS), with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Values of Potential Clinical Importance (PCI)- Part1</title>
          <description>Blood samples were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocyte, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Values of PCI - Part 2</title>
        <description>Blood samples were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Values of PCI - Part 2</title>
          <description>Blood samples were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Values of PCI - Part 3A</title>
        <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. It was conducted at Day 2 (48 hours). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Values of PCI - Part 3A</title>
          <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. It was conducted at Day 2 (48 hours). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hematology Values of PCI - Part 3B</title>
        <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. It was conducted at Day 2 (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hematology Values of PCI - Part 3B</title>
          <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of hematology parameters like hematocrit, hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. It was conducted at Day 2 (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hematocrit, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelets, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukocytes, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Chemistry Values of PCI- Part1</title>
        <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg Sodium laurilsulfate (SLS), with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 milligram (mg) + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Values of PCI- Part1</title>
          <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Chemistry Values of PCI- Part 2</title>
        <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. It was collected at Day 2 (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies, ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Values of PCI- Part 2</title>
          <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. It was collected at Day 2 (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Chemistry Values of PCI- Part 3A</title>
        <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. It was collected at (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Values of PCI- Part 3A</title>
          <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. It was collected at (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical Chemistry Values of PCI- Part 3B</title>
        <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. It was collected at Day 2 (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
        <time_frame>Day 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Chemistry Values of PCI- Part 3B</title>
          <description>Blood samples of 2 mL, via a cannula for were collected from the participants for analysis of clinical chemistry parameters like glucose, calcium, albumin, sodium and potassium. It was collected at Day 2 (48 hour). The data for number of participants, with low and high values of PCI have been reported. Safety population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Glucose, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Albumin, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, low</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, high</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Urinalysis Results by Dipstick Method-Part 1</title>
        <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis.</description>
        <time_frame>Up to Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Urinalysis Results by Dipstick Method-Part 1</title>
          <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ketone, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone 1+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone 1+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 1+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 1+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 1+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 1+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 1+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 1+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urinalysis Results by Dipstick Analysis-Part 2</title>
        <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis</description>
        <time_frame>Up to Day 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 milligram (mg) + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urinalysis Results by Dipstick Analysis-Part 2</title>
          <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ketone, trace-intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urinalysis Results by Dipstick Analysis-Part 3A</title>
        <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis.</description>
        <time_frame>Up to Day 2</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urinalysis Results by Dipstick Analysis-Part 3A</title>
          <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ketone, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone 1+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone 1+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 1+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 1+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 1+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 1+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 2+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 1+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 2+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 1+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Urinalysis Results by Dipstick Analysis-Part 3B</title>
        <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis.</description>
        <time_frame>Up to Day 2</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Urinalysis Results by Dipstick Analysis-Part 3B</title>
          <description>Urine samples were collected at Day -1 (Baseline) and 48 hour, from the participants for urinalysis, by standard dipstick method. The parameters analyzed were ketones, glucose, occult blood, and protein. The number of participants with parameters detected as trace-lysed, trace-intact, trace, 2+ and 1+ was reported. Safety Population was used for analysis.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ketone, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, 3+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace-intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ketone, 3+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 3+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose, 3+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 3+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult blood, 3+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-lysed, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-Intact, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 3+, Day -1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-lysed, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace-Intact, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, trace, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Protein, 3+, 48 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs)-Part 1</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
        <time_frame>Up to 42 days</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1,Treatment F1</title>
            <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
          </group>
          <group group_id="O2">
            <title>Part 1,Treatment F2</title>
            <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
          </group>
          <group group_id="O3">
            <title>Part 1,Treatment F3</title>
            <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
          </group>
          <group group_id="O4">
            <title>Part 1,Treatment F4</title>
            <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
          <group group_id="O5">
            <title>Part 1, Treatment R</title>
            <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs)-Part 1</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With SAEs and AEs-Part 2</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
        <time_frame>Up to 35 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2, Treatment R</title>
            <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
          </group>
          <group group_id="O2">
            <title>Part 2, Treatment FG1</title>
            <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
          </group>
          <group group_id="O3">
            <title>Part 2, Treatment FG2</title>
            <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
          </group>
          <group group_id="O4">
            <title>Part 2, Treatment FG3</title>
            <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With SAEs and AEs-Part 2</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With SAEs and AEs-Part 3A</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
        <time_frame>Up to 44 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3A,Treatment X1</title>
            <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, participants received a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
          </group>
          <group group_id="O2">
            <title>Part 3A,Treatment X2</title>
            <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
          </group>
          <group group_id="O3">
            <title>Part 3A,Treatment R1</title>
            <description>In the R1 arm, of Part 3A, , the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
          </group>
          <group group_id="O4">
            <title>Part 3A,Treatment R2</title>
            <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With SAEs and AEs-Part 3A</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With SAEs and AEs-Part 3B</title>
        <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
        <time_frame>Up to 44 days</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part 3B,Treatment Y1</title>
            <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
          </group>
          <group group_id="O2">
            <title>Part 3B,Treatment Y2</title>
            <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
          </group>
          <group group_id="O3">
            <title>Part 3B,Treatment R3</title>
            <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
          </group>
          <group group_id="O4">
            <title>Part 3B,Treatment R4</title>
            <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With SAEs and AEs-Part 3B</title>
          <description>An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or is associated with liver injury and impaired liver function. Safety population was used for analysis.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="32"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All SAEs and AEs were collected from Day 1 to up to follow-up ( up to 165 days)</time_frame>
      <desc>Safety population included all the participants enrolled into the study who received atleast one dose of investigational product, was used to assess AE's and SAE's</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1,Treatment F1</title>
          <description>In the F1 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC1- GSK3380154, TAB-A, Tablet Weight 840mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F2.</description>
        </group>
        <group group_id="E2">
          <title>Part 1,Treatment F2</title>
          <description>In the F2 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): FDC2- GSK3380154, TAB-A, Tablet Weight 840mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F3.</description>
        </group>
        <group group_id="E3">
          <title>Part 1,Treatment F3</title>
          <description>In the F3 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TABA, Tablet Weight 560mg/2mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose F4.</description>
        </group>
        <group group_id="E4">
          <title>Part 1,Treatment F4</title>
          <description>In the F4 arm of Part 1, the participants had received the FDC with dose session as (ambrisentan 10 mg + tadalafil 40 mg): GSK3380154, TAB-A, Tablet Weight 560mg/4mg SLS, with reference to the 2 monotherapy components for ambrisentan 10 mg and tadalafil 40 mg, which were taken concurrently, which evaluated bioavailability. This was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
        </group>
        <group group_id="E5">
          <title>Part 1, Treatment R</title>
          <description>In the R arm of Part 1, the participants had received the 2 monotherapies ambrisentan 10 mg and tadalafil 40 mg concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
        </group>
        <group group_id="E6">
          <title>Part 2, Treatment R</title>
          <description>Participants were administered 2 monotherapies ambrisentan and tadalafil concurrently. The tablets were taken as single oral dose, under fasting condition and was followed by a wash-out period of 7-days.</description>
        </group>
        <group group_id="E7">
          <title>Part 2, Treatment FG1</title>
          <description>Participants were administered the FDC-G1 granulation size 1 (ambrisentan 10 mg + tadalafil 40 mg) , from the formulation selected from Part 1. FG1 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG2.</description>
        </group>
        <group group_id="E8">
          <title>Part 2, Treatment FG2</title>
          <description>Participants were administered the FDC-G2 granulation size 2 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG2 was administered as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose FG3.</description>
        </group>
        <group group_id="E9">
          <title>Part 2, Treatment FG3</title>
          <description>Participants were administered the FDC-G3 granulation size 3 (ambrisentan 10 mg + tadalafil 40 mg) from the formulation selected from Part 1. FG3 was received as a single oral dose, under fasting condition and was followed by a wash-out period of 7-days, before the start of next dose R.</description>
        </group>
        <group group_id="E10">
          <title>Part 3A,Treatment X1</title>
          <description>In the X1 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg) either FG1, FG2 or FG3 (from granular formulation selected from Part 2), under fed state as a single oral dose. The fed state, particpants recived a high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose X2.</description>
        </group>
        <group group_id="E11">
          <title>Part 3A,Treatment X2</title>
          <description>In the X2 arm of Part 3A, which evaluated the bioequivalence, the participants had received FDC (ambrisentan 10 mg + tadalafil 40 mg), either FG1, FG2 or FG3 (the granular formulation selected from Part 2), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R1.</description>
        </group>
        <group group_id="E12">
          <title>Part 3A,Treatment R1</title>
          <description>In the R1 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fed state. Fed state comprised of high fat diet. This was followed by a wash-out period of 10-days, before the start of next dose R2.</description>
        </group>
        <group group_id="E13">
          <title>Part 3A,Treatment R2</title>
          <description>In the R2 arm, of Part 3A, the participants had received the 2 monotherapies, for ambrisentan 10 mg and tadalafil 40 mg, as single oral dose, under fasted state. This was followed by a wash-out period of 10-days.</description>
        </group>
        <group group_id="E14">
          <title>Part 3B,Treatment Y1</title>
          <description>In the Y1 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 40 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose Y2</description>
        </group>
        <group group_id="E15">
          <title>Part 3B,Treatment Y2</title>
          <description>In the Y2 arm of Part 3B, which evaluated bioequivalence, the participants had received FDC (ambrisentan 5 mg + tadalafil 20 mg), under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose R3.</description>
        </group>
        <group group_id="E16">
          <title>Part 3B,Treatment R3</title>
          <description>In the R3 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 40 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days, before the start of next dose of R4.</description>
        </group>
        <group group_id="E17">
          <title>Part 3B,Treatment R4</title>
          <description>In the R4 arm of Part 3B, which evaluated bioequivalence, the participants had received the 2 monotherapies, for ambrisentan 5 mg and tadalafil 20 mg, under fasted state as a single oral dose. This was followed by a wash-out period of 10-days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="22"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="21"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="22" subjects_at_risk="32"/>
                <counts group_id="E11" subjects_affected="21" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="24" subjects_at_risk="32"/>
                <counts group_id="E13" subjects_affected="22" subjects_at_risk="32"/>
                <counts group_id="E14" subjects_affected="19" subjects_at_risk="30"/>
                <counts group_id="E15" subjects_affected="17" subjects_at_risk="31"/>
                <counts group_id="E16" subjects_affected="22" subjects_at_risk="32"/>
                <counts group_id="E17" subjects_affected="13" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E12" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E13" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E14" events="3" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E16" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="33"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E14" events="4" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E16" events="4" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E12" events="5" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" events="15" subjects_affected="13" subjects_at_risk="22"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E6" events="14" subjects_affected="13" subjects_at_risk="21"/>
                <counts group_id="E7" events="10" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E8" events="15" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E9" events="11" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E10" events="18" subjects_affected="17" subjects_at_risk="32"/>
                <counts group_id="E11" events="21" subjects_affected="20" subjects_at_risk="33"/>
                <counts group_id="E12" events="24" subjects_affected="22" subjects_at_risk="32"/>
                <counts group_id="E13" events="23" subjects_affected="22" subjects_at_risk="32"/>
                <counts group_id="E14" events="18" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E15" events="13" subjects_affected="13" subjects_at_risk="31"/>
                <counts group_id="E16" events="16" subjects_affected="16" subjects_at_risk="32"/>
                <counts group_id="E17" events="10" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erection increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Priapism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="33"/>
                <counts group_id="E12" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="31"/>
                <counts group_id="E16" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E13" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

